PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 6347189-0 1983 Purification of human renin by affinity chromatography using a new peptide inhibitor of renin, H.77 (D-His-Pro-Phe-His-LeuR-Leu-Val-Tyr). dehydrosoyasaponin I 101-106 renin Homo sapiens 22-27 6347189-0 1983 Purification of human renin by affinity chromatography using a new peptide inhibitor of renin, H.77 (D-His-Pro-Phe-His-LeuR-Leu-Val-Tyr). dehydrosoyasaponin I 101-106 renin Homo sapiens 88-93 6347189-1 1983 A new affinity column for renin was prepared by coupling the isosteric peptide inhibitor of renin, H.77 (D-His-Pro-Phe-His-LeuR-Leu-Val-Tyr, where R is a reduced isosteric bond, -CH2-NH-), to activated 6-aminohexanoic acid-Sepharose 4B. dehydrosoyasaponin I 105-110 renin Homo sapiens 26-31 6347189-1 1983 A new affinity column for renin was prepared by coupling the isosteric peptide inhibitor of renin, H.77 (D-His-Pro-Phe-His-LeuR-Leu-Val-Tyr, where R is a reduced isosteric bond, -CH2-NH-), to activated 6-aminohexanoic acid-Sepharose 4B. dehydrosoyasaponin I 105-110 renin Homo sapiens 92-97 33691773-11 2021 In IDD mice, GSK3beta overexpression resulted in increased DHI, inhibition of NP cell apoptosis, alleviation of disc degeneration, and promoted mechanical and thermal pain thresholds. dehydrosoyasaponin I 59-62 glycogen synthase kinase 3 alpha Mus musculus 13-21 33995051-10 2021 The 16 postoperative interventions revealed that the effect of DHI at 14 days was better than that at 7 and 10 days for hs-CRP (p = 0.013), the 10-days treatment produced better results for CK-MB than for the other treatments (p < 0.001) and a dosage of 30 ml proved most effective for IL-6 (p < 0.001). dehydrosoyasaponin I 63-66 C-reactive protein Homo sapiens 123-126 33995051-10 2021 The 16 postoperative interventions revealed that the effect of DHI at 14 days was better than that at 7 and 10 days for hs-CRP (p = 0.013), the 10-days treatment produced better results for CK-MB than for the other treatments (p < 0.001) and a dosage of 30 ml proved most effective for IL-6 (p < 0.001). dehydrosoyasaponin I 63-66 interleukin 6 Homo sapiens 286-290 34058441-6 2021 In addition, DHI significantly ameliorated oxidative stress, reduced DNA damage, and inhibited the activation of PARP1/AIF pathway, thereby restoring cytoplasmic glycolytic activity. dehydrosoyasaponin I 13-16 poly (ADP-ribose) polymerase 1 Rattus norvegicus 113-118 34058441-6 2021 In addition, DHI significantly ameliorated oxidative stress, reduced DNA damage, and inhibited the activation of PARP1/AIF pathway, thereby restoring cytoplasmic glycolytic activity. dehydrosoyasaponin I 13-16 apoptosis inducing factor, mitochondria associated 1 Rattus norvegicus 119-122 33927611-6 2021 Immunohistochemical staining results also revealed that DHI dose-dependently diminished the protein expressions of ICAM-1 and COX-2, and suppressed the activation of microglia (ionized calcium-binding adapter molecule 1, Iba-1) and astrocyte (glial fibrillary acidic protein, GFAP) in the cerebral cortex. dehydrosoyasaponin I 56-59 intercellular adhesion molecule 1 Rattus norvegicus 115-121 33927611-6 2021 Immunohistochemical staining results also revealed that DHI dose-dependently diminished the protein expressions of ICAM-1 and COX-2, and suppressed the activation of microglia (ionized calcium-binding adapter molecule 1, Iba-1) and astrocyte (glial fibrillary acidic protein, GFAP) in the cerebral cortex. dehydrosoyasaponin I 56-59 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 126-131 33927611-6 2021 Immunohistochemical staining results also revealed that DHI dose-dependently diminished the protein expressions of ICAM-1 and COX-2, and suppressed the activation of microglia (ionized calcium-binding adapter molecule 1, Iba-1) and astrocyte (glial fibrillary acidic protein, GFAP) in the cerebral cortex. dehydrosoyasaponin I 56-59 allograft inflammatory factor 1 Rattus norvegicus 177-219 33927611-6 2021 Immunohistochemical staining results also revealed that DHI dose-dependently diminished the protein expressions of ICAM-1 and COX-2, and suppressed the activation of microglia (ionized calcium-binding adapter molecule 1, Iba-1) and astrocyte (glial fibrillary acidic protein, GFAP) in the cerebral cortex. dehydrosoyasaponin I 56-59 allograft inflammatory factor 1 Rattus norvegicus 221-226 33927611-6 2021 Immunohistochemical staining results also revealed that DHI dose-dependently diminished the protein expressions of ICAM-1 and COX-2, and suppressed the activation of microglia (ionized calcium-binding adapter molecule 1, Iba-1) and astrocyte (glial fibrillary acidic protein, GFAP) in the cerebral cortex. dehydrosoyasaponin I 56-59 glial fibrillary acidic protein Rattus norvegicus 243-274 33927611-6 2021 Immunohistochemical staining results also revealed that DHI dose-dependently diminished the protein expressions of ICAM-1 and COX-2, and suppressed the activation of microglia (ionized calcium-binding adapter molecule 1, Iba-1) and astrocyte (glial fibrillary acidic protein, GFAP) in the cerebral cortex. dehydrosoyasaponin I 56-59 glial fibrillary acidic protein Rattus norvegicus 276-280 33510801-5 2021 RNA-seq results indicated calcium ion handling and negative regulation of apoptotic process were vital processes and DHI and TMZ obviously reduced the expression of CaMK II and inhibited cleaved caspase-3 and Bax. dehydrosoyasaponin I 117-120 calcium/calmodulin dependent protein kinase II gamma Homo sapiens 165-172 33548866-10 2021 Besides, the role miR-19a and SIRT1 in DHI and components-mediated anti-autophagy responses were validated with inhibitors transfection. dehydrosoyasaponin I 39-42 microRNA 19a Homo sapiens 18-25 33548866-10 2021 Besides, the role miR-19a and SIRT1 in DHI and components-mediated anti-autophagy responses were validated with inhibitors transfection. dehydrosoyasaponin I 39-42 sirtuin 1 Homo sapiens 30-35 33548866-17 2021 For the expression of LC3, Beclin-1 and P62, DHI and its components all had significant effects. dehydrosoyasaponin I 45-48 microtubule associated protein 1 light chain 3 alpha Homo sapiens 22-25 33510801-4 2021 Administration of DHI and TMZ obviously decreased myocardial infarct size, improved ultrasonic heart function, and reduced creatine kinase (CK), lactate dehydrogenase (LDH), and glutamic oxaloacetic transaminase (AST) levels after MI. dehydrosoyasaponin I 18-21 solute carrier family 17 member 5 Homo sapiens 213-216 33456666-13 2020 The results of bisulfite sequencing revealed that the TAC-induced methylation affected the CpG site in both of Rasal1 and Rassf1 genes, and DHI treatment remarkably downregulated the promoter methylation of Rasal1 and Rassf1 in CF hearts. dehydrosoyasaponin I 140-143 RAS protein activator like 1 (GAP1 like) Mus musculus 111-117 33456666-13 2020 The results of bisulfite sequencing revealed that the TAC-induced methylation affected the CpG site in both of Rasal1 and Rassf1 genes, and DHI treatment remarkably downregulated the promoter methylation of Rasal1 and Rassf1 in CF hearts. dehydrosoyasaponin I 140-143 Ras association (RalGDS/AF-6) domain family member 1 Mus musculus 122-128 33456666-13 2020 The results of bisulfite sequencing revealed that the TAC-induced methylation affected the CpG site in both of Rasal1 and Rassf1 genes, and DHI treatment remarkably downregulated the promoter methylation of Rasal1 and Rassf1 in CF hearts. dehydrosoyasaponin I 140-143 RAS protein activator like 1 (GAP1 like) Mus musculus 207-213 33456666-13 2020 The results of bisulfite sequencing revealed that the TAC-induced methylation affected the CpG site in both of Rasal1 and Rassf1 genes, and DHI treatment remarkably downregulated the promoter methylation of Rasal1 and Rassf1 in CF hearts. dehydrosoyasaponin I 140-143 Ras association (RalGDS/AF-6) domain family member 1 Mus musculus 218-224 33456666-14 2020 Furthermore, DHI treatment upregulated the expressions of Rasal1 and Rassf1, inhibited the hyperactivity of Ras/ERK, and decreased the expressions of fibrosis-related genes. dehydrosoyasaponin I 13-16 RAS protein activator like 1 (GAP1 like) Mus musculus 58-64 33456666-14 2020 Furthermore, DHI treatment upregulated the expressions of Rasal1 and Rassf1, inhibited the hyperactivity of Ras/ERK, and decreased the expressions of fibrosis-related genes. dehydrosoyasaponin I 13-16 Ras association (RalGDS/AF-6) domain family member 1 Mus musculus 69-75 33456666-14 2020 Furthermore, DHI treatment upregulated the expressions of Rasal1 and Rassf1, inhibited the hyperactivity of Ras/ERK, and decreased the expressions of fibrosis-related genes. dehydrosoyasaponin I 13-16 mitogen-activated protein kinase 1 Mus musculus 112-115 33456666-15 2020 Notably, we found that DHI treatment markedly downregulated the expression of DNMT3B in CF hearts, while it did not affect the expressions of DNMT1, DNMT3A, and TET3. dehydrosoyasaponin I 23-26 DNA methyltransferase 3B Mus musculus 78-84 33456666-17 2020 DHI treatment alleviated CF, prevented the hypermethylation of Rasal1 and Rassf1, and downregulated DNMT3B expression in CF hearts. dehydrosoyasaponin I 0-3 RAS protein activator like 1 (GAP1 like) Mus musculus 63-69 33456666-17 2020 DHI treatment alleviated CF, prevented the hypermethylation of Rasal1 and Rassf1, and downregulated DNMT3B expression in CF hearts. dehydrosoyasaponin I 0-3 Ras association (RalGDS/AF-6) domain family member 1 Mus musculus 74-80 33456666-17 2020 DHI treatment alleviated CF, prevented the hypermethylation of Rasal1 and Rassf1, and downregulated DNMT3B expression in CF hearts. dehydrosoyasaponin I 0-3 DNA methyltransferase 3B Mus musculus 100-106 33350759-6 2020 A Spearman correlation revealed a significantly moderate positive correlation (r = .455, P < .001) between DHI and HADS scores.The emotional, functional and physical effects of vertigo on VM patients were more significant than BPPV patients. dehydrosoyasaponin I 107-110 benign paroxysmal positional vertigo Homo sapiens 227-231 33414894-8 2020 Moreover, validation results indicated that Smad3 was a putative target TF for DHI and BNC-mediated protection against cerebral ischemia. dehydrosoyasaponin I 79-82 SMAD family member 3 Mus musculus 44-49 33510801-5 2021 RNA-seq results indicated calcium ion handling and negative regulation of apoptotic process were vital processes and DHI and TMZ obviously reduced the expression of CaMK II and inhibited cleaved caspase-3 and Bax. dehydrosoyasaponin I 117-120 caspase 3 Homo sapiens 195-204 33510801-5 2021 RNA-seq results indicated calcium ion handling and negative regulation of apoptotic process were vital processes and DHI and TMZ obviously reduced the expression of CaMK II and inhibited cleaved caspase-3 and Bax. dehydrosoyasaponin I 117-120 BCL2 associated X, apoptosis regulator Homo sapiens 209-212 33510801-6 2021 Furthermore, DHI and TMZ increased p-S16-PLB, p-S16T17-PLB, CACNA1C, p-RyR2, and p-PKA expression but did not affect SERCA2a expression. dehydrosoyasaponin I 13-16 calcium voltage-gated channel subunit alpha1 C Homo sapiens 60-67 33510801-6 2021 Furthermore, DHI and TMZ increased p-S16-PLB, p-S16T17-PLB, CACNA1C, p-RyR2, and p-PKA expression but did not affect SERCA2a expression. dehydrosoyasaponin I 13-16 ryanodine receptor 2 Homo sapiens 71-75 33510801-7 2021 In addition to the enhancement of cardiac myocyte shortening amplitude, maximum shortening velocity, and calcium transients, DHI and TMZ increased sarcoplasmic reticulum calcium content and enhanced SERCA2a calcium uptake capability by upregulating the phosphorylation of PLB but did not affect calcium exclusion by NCX. dehydrosoyasaponin I 125-128 T cell leukemia homeobox 2 Homo sapiens 316-319 33510801-8 2021 In conclusion, DHI and TMZ protect against MI through inhibiting apoptosis by downregulating CaMKII pathway and enhancing cardiac myocyte contractile functions possibly through the PKA signaling pathway. dehydrosoyasaponin I 15-18 calcium/calmodulin dependent protein kinase II gamma Homo sapiens 93-99 32863935-8 2020 Following treatment of the U251 and U87 cells with DHI, changes in the expression levels of ferroptosis-associated proteins were observed; the expression level of GPX4 decreased and that of ACSL-4 increased. dehydrosoyasaponin I 51-54 glutathione peroxidase 4 Homo sapiens 163-167 33324219-7 2020 The underlying mechanism of action of DHI in maintenance of mitochondrial integrity and anti-apoptosis was detected in H9C2 cells with or without Nrf2 knockdown. dehydrosoyasaponin I 38-41 NFE2 like bZIP transcription factor 2 Rattus norvegicus 146-150 33324219-10 2020 Moreover, the Keap1/Nrf2/JNK pathway was found to be involved in DHI reducing oxidative stress and maintaining mitochondrial integrity. dehydrosoyasaponin I 65-68 Kelch-like ECH-associated protein 1 Rattus norvegicus 14-19 33324219-10 2020 Moreover, the Keap1/Nrf2/JNK pathway was found to be involved in DHI reducing oxidative stress and maintaining mitochondrial integrity. dehydrosoyasaponin I 65-68 NFE2 like bZIP transcription factor 2 Rattus norvegicus 20-24 33324219-10 2020 Moreover, the Keap1/Nrf2/JNK pathway was found to be involved in DHI reducing oxidative stress and maintaining mitochondrial integrity. dehydrosoyasaponin I 65-68 mitogen-activated protein kinase 8 Rattus norvegicus 25-28 33324219-11 2020 We revealed a novel mechanism by which DHI protected H9C2 cells against H/R injury via the Keap1/Nrf2/JNK pathway and provided a mitochondrial protectant for the treatment of myocardial I/R injury. dehydrosoyasaponin I 39-42 Kelch-like ECH-associated protein 1 Rattus norvegicus 91-96 33324219-11 2020 We revealed a novel mechanism by which DHI protected H9C2 cells against H/R injury via the Keap1/Nrf2/JNK pathway and provided a mitochondrial protectant for the treatment of myocardial I/R injury. dehydrosoyasaponin I 39-42 NFE2 like bZIP transcription factor 2 Rattus norvegicus 97-101 33324219-11 2020 We revealed a novel mechanism by which DHI protected H9C2 cells against H/R injury via the Keap1/Nrf2/JNK pathway and provided a mitochondrial protectant for the treatment of myocardial I/R injury. dehydrosoyasaponin I 39-42 mitogen-activated protein kinase 8 Rattus norvegicus 102-105 32863935-8 2020 Following treatment of the U251 and U87 cells with DHI, changes in the expression levels of ferroptosis-associated proteins were observed; the expression level of GPX4 decreased and that of ACSL-4 increased. dehydrosoyasaponin I 51-54 acyl-CoA synthetase long chain family member 4 Homo sapiens 190-196 32292340-6 2020 DHI remarkably increased the Peroxiredoxin 1 (Prx1) expression in astrocytes and reduced the expression of inflammatory factors tumor necrosis factor-alpha (TNF-alpha) and interleukin-beta (IL-1beta) after ICH. dehydrosoyasaponin I 0-3 peroxiredoxin 1 Rattus norvegicus 29-44 33261270-13 2020 DHI does not differ between sexes, it increases from C3-4 to C5-6 with a slight decrease in C6-7, while its value significantly decreases in C7-T1 (p<0.0001). dehydrosoyasaponin I 0-3 complement C6 Homo sapiens 92-96 32292340-6 2020 DHI remarkably increased the Peroxiredoxin 1 (Prx1) expression in astrocytes and reduced the expression of inflammatory factors tumor necrosis factor-alpha (TNF-alpha) and interleukin-beta (IL-1beta) after ICH. dehydrosoyasaponin I 0-3 peroxiredoxin 1 Rattus norvegicus 46-50 32292340-6 2020 DHI remarkably increased the Peroxiredoxin 1 (Prx1) expression in astrocytes and reduced the expression of inflammatory factors tumor necrosis factor-alpha (TNF-alpha) and interleukin-beta (IL-1beta) after ICH. dehydrosoyasaponin I 0-3 tumor necrosis factor Rattus norvegicus 128-155 32292340-6 2020 DHI remarkably increased the Peroxiredoxin 1 (Prx1) expression in astrocytes and reduced the expression of inflammatory factors tumor necrosis factor-alpha (TNF-alpha) and interleukin-beta (IL-1beta) after ICH. dehydrosoyasaponin I 0-3 tumor necrosis factor Rattus norvegicus 157-166 32292340-6 2020 DHI remarkably increased the Peroxiredoxin 1 (Prx1) expression in astrocytes and reduced the expression of inflammatory factors tumor necrosis factor-alpha (TNF-alpha) and interleukin-beta (IL-1beta) after ICH. dehydrosoyasaponin I 0-3 interleukin 1 alpha Rattus norvegicus 190-198 32292340-7 2020 The immediate treatment of Prx1 inhibiter chelerythrine (Che) after ICH abolished the protective effect of DHI. dehydrosoyasaponin I 107-110 peroxiredoxin 1 Rattus norvegicus 27-31 32292340-11 2020 DHI exerts antioxidative and anti-inflammatory function by increasing Prx1 in astrocytes. dehydrosoyasaponin I 0-3 peroxiredoxin 1 Rattus norvegicus 70-74 32218735-2 2020 In this study, we investigated the neuroprotective effect of DHI against cerebral ischemia-reperfusion injury mediated via the PI3K-Akt signaling pathway. dehydrosoyasaponin I 61-64 AKT serine/threonine kinase 1 Rattus norvegicus 132-135 32218735-7 2020 In addition, the expression of pro-apoptotic factors (Bad, Bax, and Bim) was significantly downregulated in the DHI group, while expression of the anti-apoptotic factor Bcl-2 was significantly upregulated, and expression of the apoptotic gene p53 was also significantly attenuated. dehydrosoyasaponin I 112-115 BCL2 associated X, apoptosis regulator Rattus norvegicus 59-62 32218735-7 2020 In addition, the expression of pro-apoptotic factors (Bad, Bax, and Bim) was significantly downregulated in the DHI group, while expression of the anti-apoptotic factor Bcl-2 was significantly upregulated, and expression of the apoptotic gene p53 was also significantly attenuated. dehydrosoyasaponin I 112-115 Bcl2-like 11 Rattus norvegicus 68-71 32218735-7 2020 In addition, the expression of pro-apoptotic factors (Bad, Bax, and Bim) was significantly downregulated in the DHI group, while expression of the anti-apoptotic factor Bcl-2 was significantly upregulated, and expression of the apoptotic gene p53 was also significantly attenuated. dehydrosoyasaponin I 112-115 BCL2, apoptosis regulator Rattus norvegicus 169-174 32218735-7 2020 In addition, the expression of pro-apoptotic factors (Bad, Bax, and Bim) was significantly downregulated in the DHI group, while expression of the anti-apoptotic factor Bcl-2 was significantly upregulated, and expression of the apoptotic gene p53 was also significantly attenuated. dehydrosoyasaponin I 112-115 Wistar clone pR53P1 p53 pseudogene Rattus norvegicus 243-246 32218735-9 2020 Thus, our results confirmed the neuroprotective effects of DHI in rats with ischemia-reperfusion injury and indicate that these effects on the brain are partly generated by activation of the PI3K-Akt signaling pathway. dehydrosoyasaponin I 59-62 AKT serine/threonine kinase 1 Rattus norvegicus 196-199 31534463-9 2019 Moreover, the expression of inflammatory factors TNF-alpha, IL-1beta, and IL-6 was significantly reduced in the treated DHI group. dehydrosoyasaponin I 120-123 tumor necrosis factor Rattus norvegicus 49-58 31532402-1 2019 In this work, a sensing nanochannel based on a N-[3-(triethoxysilyl)propyl]-4,5-dihydroimidazole (DHI) modified nanopipette was prepared and characterized for the ultrasensitive detection of cobalt ions (Co2+) in aqueous solutions. dehydrosoyasaponin I 98-101 complement C2 Homo sapiens 204-207 31534463-9 2019 Moreover, the expression of inflammatory factors TNF-alpha, IL-1beta, and IL-6 was significantly reduced in the treated DHI group. dehydrosoyasaponin I 120-123 interleukin 1 beta Rattus norvegicus 60-68 31534463-9 2019 Moreover, the expression of inflammatory factors TNF-alpha, IL-1beta, and IL-6 was significantly reduced in the treated DHI group. dehydrosoyasaponin I 120-123 interleukin 6 Rattus norvegicus 74-78 31534463-10 2019 Mechanistically, DHI downregulated the inflammatory transcription factor NF-kappaB (as reflected by inhibition of NF-kappaB p65 nuclear translocation and phosphorylation of the IkappaBalpha). dehydrosoyasaponin I 17-20 synaptotagmin 1 Rattus norvegicus 124-127 31534463-10 2019 Mechanistically, DHI downregulated the inflammatory transcription factor NF-kappaB (as reflected by inhibition of NF-kappaB p65 nuclear translocation and phosphorylation of the IkappaBalpha). dehydrosoyasaponin I 17-20 NFKB inhibitor alpha Rattus norvegicus 177-189 31089808-10 2019 Higher DHI scores were associated with lateral canal BPPV [95% CI (1.59-13.95), p = 0.01] and female gender [95% CI (0.74-15.52), p = 0.03]. dehydrosoyasaponin I 7-10 benign paroxysmal positional vertigo Homo sapiens 53-57 31531183-13 2019 DHI treatment significantly reduced the levels of TNF-alpha, TGF-beta1, and PAI and increased the expression levels of MMP9, Nrf2, and t-PA in the adhesion tissues. dehydrosoyasaponin I 0-3 tumor necrosis factor Rattus norvegicus 50-59 31531183-13 2019 DHI treatment significantly reduced the levels of TNF-alpha, TGF-beta1, and PAI and increased the expression levels of MMP9, Nrf2, and t-PA in the adhesion tissues. dehydrosoyasaponin I 0-3 transforming growth factor, beta 1 Rattus norvegicus 61-70 31531183-13 2019 DHI treatment significantly reduced the levels of TNF-alpha, TGF-beta1, and PAI and increased the expression levels of MMP9, Nrf2, and t-PA in the adhesion tissues. dehydrosoyasaponin I 0-3 serpin family E member 1 Rattus norvegicus 76-79 31531183-13 2019 DHI treatment significantly reduced the levels of TNF-alpha, TGF-beta1, and PAI and increased the expression levels of MMP9, Nrf2, and t-PA in the adhesion tissues. dehydrosoyasaponin I 0-3 matrix metallopeptidase 9 Rattus norvegicus 119-123 31531183-13 2019 DHI treatment significantly reduced the levels of TNF-alpha, TGF-beta1, and PAI and increased the expression levels of MMP9, Nrf2, and t-PA in the adhesion tissues. dehydrosoyasaponin I 0-3 NFE2 like bZIP transcription factor 2 Rattus norvegicus 125-129 31531183-13 2019 DHI treatment significantly reduced the levels of TNF-alpha, TGF-beta1, and PAI and increased the expression levels of MMP9, Nrf2, and t-PA in the adhesion tissues. dehydrosoyasaponin I 0-3 plasminogen activator, tissue type Rattus norvegicus 135-139 31306371-7 2019 By estimating the levels of serum insulin resistance-related indexes and protein expression of GLUT-4, DHI treatment dramatically inhibited the levels of fasting serum NEFA and fasting serum insulin and promoted the protein expression of GLUT-4 in aortas of the HFD-induced atherosclerotic mice. dehydrosoyasaponin I 103-106 solute carrier family 2 (facilitated glucose transporter), member 4 Mus musculus 95-101 31306371-7 2019 By estimating the levels of serum insulin resistance-related indexes and protein expression of GLUT-4, DHI treatment dramatically inhibited the levels of fasting serum NEFA and fasting serum insulin and promoted the protein expression of GLUT-4 in aortas of the HFD-induced atherosclerotic mice. dehydrosoyasaponin I 103-106 solute carrier family 2 (facilitated glucose transporter), member 4 Mus musculus 238-244 31306371-8 2019 Moreover, according to the hints provided by microarray-based transcriptional profiling, the results demonstrated that DHI treatment also promoted the activation of PI3K/AKT insulin signaling pathway induced by IRS-1 in aortas of HFD-induced atherosclerotic mice. dehydrosoyasaponin I 119-122 thymoma viral proto-oncogene 1 Mus musculus 170-173 31306371-8 2019 Moreover, according to the hints provided by microarray-based transcriptional profiling, the results demonstrated that DHI treatment also promoted the activation of PI3K/AKT insulin signaling pathway induced by IRS-1 in aortas of HFD-induced atherosclerotic mice. dehydrosoyasaponin I 119-122 insulin receptor substrate 1 Mus musculus 211-216 31306371-9 2019 Furthermore, in an ox-LDL-induced macrophage model, the activation of PI3k/AKT signaling pathway also effectively functioned in the process of DHI inhibiting macrophage lipid accumulation. dehydrosoyasaponin I 143-146 thymoma viral proto-oncogene 1 Mus musculus 75-78 31306371-10 2019 CONCLUSIONS: These results highlight that DHI treatment attenuates atherosclerosis and macrophage lipid accumulation by promoting the activation of PI3K/AKT insulin signaling pathway. dehydrosoyasaponin I 42-45 thymoma viral proto-oncogene 1 Mus musculus 153-156 31035054-9 2019 At last we tested the effect of DHI and three chemical constituents of DHI (danshensu; lithospermic acid, LA; salvianolic acid D, SaD) on EPCs level and expression of Akt, eNOS and MMP-9 in bone marrow cells of myocardial infarction (MI) mice. dehydrosoyasaponin I 71-74 thymoma viral proto-oncogene 1 Mus musculus 167-170 31410197-11 2019 Pharmacological upstream blocking by CD44 antibody or downstream blockade of YAP by DHI or VP could attenuate fibroblast migration, invasion, proliferation, and collagen deposition. dehydrosoyasaponin I 84-87 Yes1 associated transcriptional regulator Homo sapiens 77-80 31308689-12 2019 In terms of mechanism, DHI may inhibit both the transcriptional activity and the total protein level of beta-catenin. dehydrosoyasaponin I 23-26 catenin (cadherin associated protein), beta 1 Mus musculus 104-116 31308689-13 2019 Conclusion: DHI may inhibit the proliferation, migration, and invasion as well as induce the apoptosis of osteosarcoma cells, possibly through suppressing the Wnt/beta-catenin signaling pathway. dehydrosoyasaponin I 12-15 catenin (cadherin associated protein), beta 1 Mus musculus 163-175 31035054-14 2019 DHI promoted EPCs mobilization via upregulating the expression of Akt, eNOS and MMP-9 in BM. dehydrosoyasaponin I 0-3 AKT serine/threonine kinase 1 Homo sapiens 66-69 31035054-14 2019 DHI promoted EPCs mobilization via upregulating the expression of Akt, eNOS and MMP-9 in BM. dehydrosoyasaponin I 0-3 nitric oxide synthase 3 Homo sapiens 71-75 31035054-14 2019 DHI promoted EPCs mobilization via upregulating the expression of Akt, eNOS and MMP-9 in BM. dehydrosoyasaponin I 0-3 matrix metallopeptidase 9 Homo sapiens 80-85 30520061-6 2019 The relative induction ratios of DHI on CYP1A2, CYP2B6 and CYP3A4 activity were calculated by LC-MS/MS. dehydrosoyasaponin I 33-36 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 40-46 30520061-6 2019 The relative induction ratios of DHI on CYP1A2, CYP2B6 and CYP3A4 activity were calculated by LC-MS/MS. dehydrosoyasaponin I 33-36 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 48-54 30520061-6 2019 The relative induction ratios of DHI on CYP1A2, CYP2B6 and CYP3A4 activity were calculated by LC-MS/MS. dehydrosoyasaponin I 33-36 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 59-65 30520061-8 2019 The LC-MS/MS data showed DHI intensively inhibit CYP2A6 activity and the intensity of inhibition was followed by CYP2C8, CYP3A4, CYP2C19, CYP2B6, CYP2D6, CYP1A2, CYP2E1 and CYP2C9 in vitro. dehydrosoyasaponin I 25-28 cytochrome P450 family 2 subfamily A member 6 Homo sapiens 49-55 30520061-8 2019 The LC-MS/MS data showed DHI intensively inhibit CYP2A6 activity and the intensity of inhibition was followed by CYP2C8, CYP3A4, CYP2C19, CYP2B6, CYP2D6, CYP1A2, CYP2E1 and CYP2C9 in vitro. dehydrosoyasaponin I 25-28 cytochrome P450 family 2 subfamily C member 8 Homo sapiens 113-119 30520061-8 2019 The LC-MS/MS data showed DHI intensively inhibit CYP2A6 activity and the intensity of inhibition was followed by CYP2C8, CYP3A4, CYP2C19, CYP2B6, CYP2D6, CYP1A2, CYP2E1 and CYP2C9 in vitro. dehydrosoyasaponin I 25-28 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 121-127 30520061-8 2019 The LC-MS/MS data showed DHI intensively inhibit CYP2A6 activity and the intensity of inhibition was followed by CYP2C8, CYP3A4, CYP2C19, CYP2B6, CYP2D6, CYP1A2, CYP2E1 and CYP2C9 in vitro. dehydrosoyasaponin I 25-28 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 129-136 30520061-8 2019 The LC-MS/MS data showed DHI intensively inhibit CYP2A6 activity and the intensity of inhibition was followed by CYP2C8, CYP3A4, CYP2C19, CYP2B6, CYP2D6, CYP1A2, CYP2E1 and CYP2C9 in vitro. dehydrosoyasaponin I 25-28 cytochrome P450 family 2 subfamily B member 6 Homo sapiens 138-144 30520061-8 2019 The LC-MS/MS data showed DHI intensively inhibit CYP2A6 activity and the intensity of inhibition was followed by CYP2C8, CYP3A4, CYP2C19, CYP2B6, CYP2D6, CYP1A2, CYP2E1 and CYP2C9 in vitro. dehydrosoyasaponin I 25-28 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 146-152 30520061-8 2019 The LC-MS/MS data showed DHI intensively inhibit CYP2A6 activity and the intensity of inhibition was followed by CYP2C8, CYP3A4, CYP2C19, CYP2B6, CYP2D6, CYP1A2, CYP2E1 and CYP2C9 in vitro. dehydrosoyasaponin I 25-28 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 154-160 30520061-8 2019 The LC-MS/MS data showed DHI intensively inhibit CYP2A6 activity and the intensity of inhibition was followed by CYP2C8, CYP3A4, CYP2C19, CYP2B6, CYP2D6, CYP1A2, CYP2E1 and CYP2C9 in vitro. dehydrosoyasaponin I 25-28 cytochrome P450 family 2 subfamily E member 1 Homo sapiens 162-168 30520061-8 2019 The LC-MS/MS data showed DHI intensively inhibit CYP2A6 activity and the intensity of inhibition was followed by CYP2C8, CYP3A4, CYP2C19, CYP2B6, CYP2D6, CYP1A2, CYP2E1 and CYP2C9 in vitro. dehydrosoyasaponin I 25-28 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 173-179 30520061-9 2019 The results of RT-PCR showed that there is a certain induction of DHI on CYP3A4 mRNA in human primary hepatocytes in vitro. dehydrosoyasaponin I 66-69 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 73-79 29578591-4 2018 The results showed that DHI inhibited CYP2C19, CYP2D6, CYP3A4, CYP2E1 and CYP2C9 with IC50 values of 1.26, 1.42, 1.63, 1.10 and 1.67% (v/v), respectively. dehydrosoyasaponin I 24-27 cytochrome P450 family 2 subfamily C member 19 Homo sapiens 38-45 30031913-4 2018 The findings indicated that Glu/Gly was a biomarker and Glu-GLT-1/Gly-GlyRalpha was the core unit regulated by DHI. dehydrosoyasaponin I 111-114 solute carrier family 1 member 2 Homo sapiens 60-65 30031913-6 2018 GlyRalpha was identified as the upstream target and GLT-1 as the downstream target by inhibiting or activating GlyRalpha, indicating that DHI has two dose-dependent regulatory modes. dehydrosoyasaponin I 138-141 solute carrier family 1 member 2 Homo sapiens 52-57 30883499-10 2019 Significant differences existed between the 2 DHI groups for all scores: VVAS (P = 0.0002), SMD1 (P = 0.02), and SMDavg (P = 0.0001). dehydrosoyasaponin I 46-49 small nuclear ribonucleoprotein D1 polypeptide Homo sapiens 92-96 30863452-6 2019 Systematic analysis of the created TCMP-Compound-Target-Disease network revealed that DHI and NXT shared common targets such as PTGS2, F2, ADRB1, IL6, ALDH2, and CCL2, which were involved in the vasomotor system regulation, blood-brain barrier disruption, redox imbalance, neurotrophin activity, and brain inflammation. dehydrosoyasaponin I 86-89 prostaglandin-endoperoxide synthase 2 Homo sapiens 128-133 30863452-6 2019 Systematic analysis of the created TCMP-Compound-Target-Disease network revealed that DHI and NXT shared common targets such as PTGS2, F2, ADRB1, IL6, ALDH2, and CCL2, which were involved in the vasomotor system regulation, blood-brain barrier disruption, redox imbalance, neurotrophin activity, and brain inflammation. dehydrosoyasaponin I 86-89 adrenoceptor beta 1 Homo sapiens 139-144 30863452-6 2019 Systematic analysis of the created TCMP-Compound-Target-Disease network revealed that DHI and NXT shared common targets such as PTGS2, F2, ADRB1, IL6, ALDH2, and CCL2, which were involved in the vasomotor system regulation, blood-brain barrier disruption, redox imbalance, neurotrophin activity, and brain inflammation. dehydrosoyasaponin I 86-89 interleukin 6 Homo sapiens 146-149 30863452-6 2019 Systematic analysis of the created TCMP-Compound-Target-Disease network revealed that DHI and NXT shared common targets such as PTGS2, F2, ADRB1, IL6, ALDH2, and CCL2, which were involved in the vasomotor system regulation, blood-brain barrier disruption, redox imbalance, neurotrophin activity, and brain inflammation. dehydrosoyasaponin I 86-89 aldehyde dehydrogenase 2 family member Homo sapiens 151-156 30863452-6 2019 Systematic analysis of the created TCMP-Compound-Target-Disease network revealed that DHI and NXT shared common targets such as PTGS2, F2, ADRB1, IL6, ALDH2, and CCL2, which were involved in the vasomotor system regulation, blood-brain barrier disruption, redox imbalance, neurotrophin activity, and brain inflammation. dehydrosoyasaponin I 86-89 C-C motif chemokine ligand 2 Homo sapiens 162-166 30863452-6 2019 Systematic analysis of the created TCMP-Compound-Target-Disease network revealed that DHI and NXT shared common targets such as PTGS2, F2, ADRB1, IL6, ALDH2, and CCL2, which were involved in the vasomotor system regulation, blood-brain barrier disruption, redox imbalance, neurotrophin activity, and brain inflammation. dehydrosoyasaponin I 86-89 brain derived neurotrophic factor Homo sapiens 273-285 29578591-4 2018 The results showed that DHI inhibited CYP2C19, CYP2D6, CYP3A4, CYP2E1 and CYP2C9 with IC50 values of 1.26, 1.42, 1.63, 1.10 and 1.67% (v/v), respectively. dehydrosoyasaponin I 24-27 cytochrome P450 family 2 subfamily D member 6 Homo sapiens 47-53 29578591-4 2018 The results showed that DHI inhibited CYP2C19, CYP2D6, CYP3A4, CYP2E1 and CYP2C9 with IC50 values of 1.26, 1.42, 1.63, 1.10 and 1.67% (v/v), respectively. dehydrosoyasaponin I 24-27 cytochrome P450 family 2 subfamily E member 1 Homo sapiens 63-69 29578591-4 2018 The results showed that DHI inhibited CYP2C19, CYP2D6, CYP3A4, CYP2E1 and CYP2C9 with IC50 values of 1.26, 1.42, 1.63, 1.10 and 1.67% (v/v), respectively. dehydrosoyasaponin I 24-27 cytochrome P450 family 2 subfamily C member 9 Homo sapiens 74-80 30093864-8 2018 Our results showed that DHI could promote the expression of CXC chemokine receptor 4 in MSC and enhance the expression of stromal cell-derived factor-1 in myocardium, and this effect can be inhibited by AMD3100 (an SDF1/CXCR4 antagonist). dehydrosoyasaponin I 24-27 chemokine (C-X-C motif) ligand 12 Mus musculus 122-151 30093864-8 2018 Our results showed that DHI could promote the expression of CXC chemokine receptor 4 in MSC and enhance the expression of stromal cell-derived factor-1 in myocardium, and this effect can be inhibited by AMD3100 (an SDF1/CXCR4 antagonist). dehydrosoyasaponin I 24-27 chemokine (C-X-C motif) ligand 12 Mus musculus 215-219 30093864-8 2018 Our results showed that DHI could promote the expression of CXC chemokine receptor 4 in MSC and enhance the expression of stromal cell-derived factor-1 in myocardium, and this effect can be inhibited by AMD3100 (an SDF1/CXCR4 antagonist). dehydrosoyasaponin I 24-27 chemokine (C-X-C motif) receptor 4 Mus musculus 220-225 30093864-9 2018 Additionally, MSC in combination with DHI interfered with MI in mice and this signifies that when combined, the duo could the expression of vascular endothelial growth factor (VEGF) in the marginal zone of infarction compared with when either MSC or DHI are used individually. dehydrosoyasaponin I 38-41 vascular endothelial growth factor A Mus musculus 140-174 30093864-9 2018 Additionally, MSC in combination with DHI interfered with MI in mice and this signifies that when combined, the duo could the expression of vascular endothelial growth factor (VEGF) in the marginal zone of infarction compared with when either MSC or DHI are used individually. dehydrosoyasaponin I 38-41 vascular endothelial growth factor A Mus musculus 176-180 30093864-10 2018 Based on these results, we conclude that DHI enhances the residence of MSCs in cardiac tissue by modulating the SDF1/CXCR4 signaling pathway. dehydrosoyasaponin I 41-44 chemokine (C-X-C motif) ligand 12 Mus musculus 112-116 30093864-10 2018 Based on these results, we conclude that DHI enhances the residence of MSCs in cardiac tissue by modulating the SDF1/CXCR4 signaling pathway. dehydrosoyasaponin I 41-44 chemokine (C-X-C motif) receptor 4 Mus musculus 117-122 29849705-6 2018 These data show that DHI could delay the progress of DKD, and the effect might be achieved in part by activating the PPARgamma signaling pathway. dehydrosoyasaponin I 21-24 peroxisome proliferator-activated receptor gamma Rattus norvegicus 117-126 29393225-10 2018 The intervention with DHI potently suppressed the renal injury biomarker (KIM-1) and kidney lesions compared to the untreated hypertensive subjects. dehydrosoyasaponin I 22-25 hepatitis A virus cellular receptor 1 Rattus norvegicus 74-79 29342843-6 2018 For the protonated noncovalent complexes of His enantiomers with tripeptides (AAA, SAA, ASA, and AAS), protonated His was observed in the spectra, except for those of heterochiral H+(d-His)SAA and H+(d-His)AAS, indicating that d-His did not accept protons from the SAA and AAS in the noncovalent complexes. dehydrosoyasaponin I 200-205 serum amyloid A1 cluster Homo sapiens 83-86 29342843-6 2018 For the protonated noncovalent complexes of His enantiomers with tripeptides (AAA, SAA, ASA, and AAS), protonated His was observed in the spectra, except for those of heterochiral H+(d-His)SAA and H+(d-His)AAS, indicating that d-His did not accept protons from the SAA and AAS in the noncovalent complexes. dehydrosoyasaponin I 200-205 serum amyloid A1 cluster Homo sapiens 83-86 29681849-10 2018 Results:In vitro, plasmin activity assays showed that the combination of t-PA with DHI at about 1:1.6 w/v ratio increased by almost 1.4-fold the plasmin-generating capability of t-PA. dehydrosoyasaponin I 83-86 plasminogen activator, tissue type Rattus norvegicus 178-182 29681849-11 2018 In vivo experiments, the results showed that the combination of Danhong injection (4 mL/kg) and t-PA (2.5 mg/kg) could extend the t-PA treatment time windows to 4.5 h. And the combination t-PA (2.5 mg/kg) with DHI (4 mL/kg) ameliorated neurological score, cerebral infarction, brain edema, brain hemorrhage, and BBB disruption. dehydrosoyasaponin I 210-213 plasminogen activator, tissue type Rattus norvegicus 96-100 29632486-5 2018 Secondly, bioinformatic analyses for the 429 differentially expressed genes (DEGs) regulated by DHI treatment pointed out ECM-receptor interaction, neuroactive ligand-receptor interaction, and endocytosis as the top three biological processes, while Toll-like recptor 4 (TLR4) as the most relavant singaling molecule. dehydrosoyasaponin I 96-99 toll-like receptor 4 Rattus norvegicus 250-269 29632486-5 2018 Secondly, bioinformatic analyses for the 429 differentially expressed genes (DEGs) regulated by DHI treatment pointed out ECM-receptor interaction, neuroactive ligand-receptor interaction, and endocytosis as the top three biological processes, while Toll-like recptor 4 (TLR4) as the most relavant singaling molecule. dehydrosoyasaponin I 96-99 toll-like receptor 4 Rattus norvegicus 271-275 29632486-6 2018 Lastly, we provided evidences showing that DHI might directly protect primary astrocytes from oxygen and glucose deprivation/re-oxygenation (OGD/Re) injury, the effects of which was associated with LAMC2 and ADRB3, two DEGs related to the top three biological processes according to transcriptomic analysis. dehydrosoyasaponin I 43-46 laminin subunit gamma 2 Rattus norvegicus 198-203 29632486-6 2018 Lastly, we provided evidences showing that DHI might directly protect primary astrocytes from oxygen and glucose deprivation/re-oxygenation (OGD/Re) injury, the effects of which was associated with LAMC2 and ADRB3, two DEGs related to the top three biological processes according to transcriptomic analysis. dehydrosoyasaponin I 43-46 adrenoceptor beta 3 Rattus norvegicus 208-213 29632486-7 2018 In conlusion, we reported that DHI might work through maintaining the integrity for brain-blood barrier and to regulate TLR4-related signaling pathway to diminish the inflammation, therefore, effectively improved the outcomes of IRI. dehydrosoyasaponin I 31-34 toll-like receptor 4 Rattus norvegicus 120-124 29552083-10 2018 DHI treatment significantly alleviated mechanical allodynia at the end of the study and downregulated the expression of phosphorylated ERK1/2 in spinal cord. dehydrosoyasaponin I 0-3 mitogen activated protein kinase 3 Rattus norvegicus 135-141 29552083-11 2018 In addition, DHI treatment also elevated brain-derived neurotrophic factor (BDNF) level in sciatic nerve of DPN rat. dehydrosoyasaponin I 13-16 brain-derived neurotrophic factor Rattus norvegicus 41-74 29552083-11 2018 In addition, DHI treatment also elevated brain-derived neurotrophic factor (BDNF) level in sciatic nerve of DPN rat. dehydrosoyasaponin I 13-16 brain-derived neurotrophic factor Rattus norvegicus 76-80 29552083-14 2018 We demonstrated that DHI was able to alleviate mechanical allodynia in diabetic neuropathy rat through inhibiting the activation of ERK1/2. dehydrosoyasaponin I 21-24 mitogen activated protein kinase 3 Rattus norvegicus 132-138 29552083-15 2018 The reduction of BDNF content in sciatic nerve was also partially reversed by DHI treatment. dehydrosoyasaponin I 78-81 brain-derived neurotrophic factor Rattus norvegicus 17-21 29393225-11 2018 Microarray analysis revealed that among the 124 genes that were differentially expressed by DHI treatment in SHR kidney, down-regulation of renal myoglobin (Mb) gene was the most prominent and was subsequently confirmed by qRT-PCR and Western blot analysis. dehydrosoyasaponin I 92-95 myoglobin Rattus norvegicus 146-155 29393225-11 2018 Microarray analysis revealed that among the 124 genes that were differentially expressed by DHI treatment in SHR kidney, down-regulation of renal myoglobin (Mb) gene was the most prominent and was subsequently confirmed by qRT-PCR and Western blot analysis. dehydrosoyasaponin I 92-95 myoglobin Rattus norvegicus 157-159 29393225-12 2018 CONCLUSION: Hypertension-induced renal injury in SHR may be alleviated by DHI in part by local suppression of Kidney injury molecule-1 and down-regulation of Myoglobin. dehydrosoyasaponin I 74-77 hepatitis A virus cellular receptor 1 Rattus norvegicus 110-134 29393225-12 2018 CONCLUSION: Hypertension-induced renal injury in SHR may be alleviated by DHI in part by local suppression of Kidney injury molecule-1 and down-regulation of Myoglobin. dehydrosoyasaponin I 74-77 myoglobin Rattus norvegicus 158-167 29187820-8 2017 Based on global components analysis, XI and DGI were the worst infusion solutions for DHI. dehydrosoyasaponin I 86-89 desmoglein 1 Homo sapiens 44-47 29187820-10 2017 In conclusion, as evaluated by the established comprehensive strategy, GS was the best infusion solution, however, XI and DGI were the worst infusion solutions for DHI. dehydrosoyasaponin I 164-167 desmoglein 1 Homo sapiens 122-125 29187820-11 2017 In the compatibility of DHI and XI or DGI, salvianolic acids in DHI would be degraded, resulting in the reduction of original composition and generation of new components, and leading to the changes of biological activities. dehydrosoyasaponin I 64-67 desmoglein 1 Homo sapiens 38-41 28944859-4 2017 The myeloperoxidase activity, malondiadelhyde level and superoxide dismutase activity determination demonstrated the anti-inflammatory and anti-oxidative properties of DHI. dehydrosoyasaponin I 168-171 myeloperoxidase Rattus norvegicus 4-19 27930695-0 2016 Coordinated Activation of VEGF/VEGFR-2 and PPARdelta Pathways by a Multi-Component Chinese Medicine DHI Accelerated Recovery from Peripheral Arterial Disease in Type 2 Diabetic Mice. dehydrosoyasaponin I 100-103 vascular endothelial growth factor A Mus musculus 26-30 28257144-10 2017 KEY RESULTS: In BDL rats, DHI administration attenuated liver necrosis, bile duct proliferation and collagen accumulation and reduced the expression of genes associated with fibrogenesis, including Tgfb1, Mmp-2, Acta2 and Col1a1. dehydrosoyasaponin I 26-29 transforming growth factor, beta 1 Rattus norvegicus 198-203 28257144-10 2017 KEY RESULTS: In BDL rats, DHI administration attenuated liver necrosis, bile duct proliferation and collagen accumulation and reduced the expression of genes associated with fibrogenesis, including Tgfb1, Mmp-2, Acta2 and Col1a1. dehydrosoyasaponin I 26-29 matrix metallopeptidase 2 Rattus norvegicus 205-210 28257144-10 2017 KEY RESULTS: In BDL rats, DHI administration attenuated liver necrosis, bile duct proliferation and collagen accumulation and reduced the expression of genes associated with fibrogenesis, including Tgfb1, Mmp-2, Acta2 and Col1a1. dehydrosoyasaponin I 26-29 actin alpha 2, smooth muscle Rattus norvegicus 212-217 28257144-10 2017 KEY RESULTS: In BDL rats, DHI administration attenuated liver necrosis, bile duct proliferation and collagen accumulation and reduced the expression of genes associated with fibrogenesis, including Tgfb1, Mmp-2, Acta2 and Col1a1. dehydrosoyasaponin I 26-29 collagen type I alpha 1 chain Rattus norvegicus 222-228 28257144-11 2017 DHI (1, 5, 10 mumol L-1 ) time- and dose-dependently suppressed the protein level of COL1A1, TGFbeta1 and alpha-SMA in LX-2 cells and rat pHSCs. dehydrosoyasaponin I 0-3 collagen type I alpha 1 chain Homo sapiens 85-91 28257144-11 2017 DHI (1, 5, 10 mumol L-1 ) time- and dose-dependently suppressed the protein level of COL1A1, TGFbeta1 and alpha-SMA in LX-2 cells and rat pHSCs. dehydrosoyasaponin I 0-3 transforming growth factor beta 1 Homo sapiens 93-101 28257144-12 2017 Furthermore, DHI blocked the nuclear translocation of YAP, which inhibited the YAP/TEAD2 interaction and its downstream fibrogenic genes, connective tissue growth factor, SOX4 and survivin. dehydrosoyasaponin I 13-16 Yes1 associated transcriptional regulator Rattus norvegicus 54-57 28257144-12 2017 Furthermore, DHI blocked the nuclear translocation of YAP, which inhibited the YAP/TEAD2 interaction and its downstream fibrogenic genes, connective tissue growth factor, SOX4 and survivin. dehydrosoyasaponin I 13-16 Yes1 associated transcriptional regulator Rattus norvegicus 79-82 28257144-12 2017 Furthermore, DHI blocked the nuclear translocation of YAP, which inhibited the YAP/TEAD2 interaction and its downstream fibrogenic genes, connective tissue growth factor, SOX4 and survivin. dehydrosoyasaponin I 13-16 TEA domain transcription factor 2 Rattus norvegicus 83-88 28257144-12 2017 Furthermore, DHI blocked the nuclear translocation of YAP, which inhibited the YAP/TEAD2 interaction and its downstream fibrogenic genes, connective tissue growth factor, SOX4 and survivin. dehydrosoyasaponin I 13-16 cellular communication network factor 2 Rattus norvegicus 138-169 28257144-12 2017 Furthermore, DHI blocked the nuclear translocation of YAP, which inhibited the YAP/TEAD2 interaction and its downstream fibrogenic genes, connective tissue growth factor, SOX4 and survivin. dehydrosoyasaponin I 13-16 SRY-box transcription factor 4 Rattus norvegicus 171-175 28257144-14 2017 CONCLUSIONS AND IMPLICATIONS: DHI exerts anti-fibrotic effects in BDL rats, LX-2 cells and rat pHSCs by inhibiting the YAP and TEAD2 complex and stimulating autophagy. dehydrosoyasaponin I 30-33 Yes1 associated transcriptional regulator Rattus norvegicus 119-122 28257144-14 2017 CONCLUSIONS AND IMPLICATIONS: DHI exerts anti-fibrotic effects in BDL rats, LX-2 cells and rat pHSCs by inhibiting the YAP and TEAD2 complex and stimulating autophagy. dehydrosoyasaponin I 30-33 TEA domain transcription factor 2 Rattus norvegicus 127-132 27889668-2 2017 In this study, a simple and efficient in vitro method based on ultrafiltration LC-MS and molecular modeling has been developed to study the human serum albumin (HSA) binding of the compounds in DHI. dehydrosoyasaponin I 194-197 albumin Homo sapiens 146-159 27729285-8 2016 TGF-beta1 protein and fibrosis-related proteins MMP-2 and MMP-9 were up-regulated after MI, and they were significantly suppressed by the administration of DHI(p<0.05 and p<0.01, respectively). dehydrosoyasaponin I 156-159 transforming growth factor, beta 1 Rattus norvegicus 0-9 27729285-8 2016 TGF-beta1 protein and fibrosis-related proteins MMP-2 and MMP-9 were up-regulated after MI, and they were significantly suppressed by the administration of DHI(p<0.05 and p<0.01, respectively). dehydrosoyasaponin I 156-159 matrix metallopeptidase 2 Rattus norvegicus 48-53 27729285-8 2016 TGF-beta1 protein and fibrosis-related proteins MMP-2 and MMP-9 were up-regulated after MI, and they were significantly suppressed by the administration of DHI(p<0.05 and p<0.01, respectively). dehydrosoyasaponin I 156-159 matrix metallopeptidase 9 Rattus norvegicus 58-63 27729285-9 2016 Moreover, DHI improved the mRNA expression of VEGF and increased the blood vessel density of myocardial infarct border zone. dehydrosoyasaponin I 10-13 vascular endothelial growth factor A Rattus norvegicus 46-50 27729285-10 2016 DHI decreased the expression of cell apoptosis protein of caspase-3 and increased the anti-apoptotic protein, bcl-2. dehydrosoyasaponin I 0-3 caspase 3 Rattus norvegicus 58-67 27729285-10 2016 DHI decreased the expression of cell apoptosis protein of caspase-3 and increased the anti-apoptotic protein, bcl-2. dehydrosoyasaponin I 0-3 BCL2, apoptosis regulator Rattus norvegicus 110-115 27930695-0 2016 Coordinated Activation of VEGF/VEGFR-2 and PPARdelta Pathways by a Multi-Component Chinese Medicine DHI Accelerated Recovery from Peripheral Arterial Disease in Type 2 Diabetic Mice. dehydrosoyasaponin I 100-103 kinase insert domain protein receptor Mus musculus 31-38 27930695-0 2016 Coordinated Activation of VEGF/VEGFR-2 and PPARdelta Pathways by a Multi-Component Chinese Medicine DHI Accelerated Recovery from Peripheral Arterial Disease in Type 2 Diabetic Mice. dehydrosoyasaponin I 100-103 peroxisome proliferator activator receptor delta Mus musculus 43-52 27930695-6 2016 Bioluminescent imaging demonstrated a continuous ischemia-induced vascular endothelial growth factor receptor 2 (VEGFR-2) gene expressions with a peak time coincident with the maximal DHI stimulation. dehydrosoyasaponin I 184-187 kinase insert domain protein receptor Mus musculus 66-111 27930695-6 2016 Bioluminescent imaging demonstrated a continuous ischemia-induced vascular endothelial growth factor receptor 2 (VEGFR-2) gene expressions with a peak time coincident with the maximal DHI stimulation. dehydrosoyasaponin I 184-187 kinase insert domain protein receptor Mus musculus 113-120 27930695-8 2016 DHI administration upregulated the expression of vascular endothelial growth factor A (VEGF-A) and VEGF receptor-2 (VEGFR-2) in ischemic muscle. dehydrosoyasaponin I 0-3 vascular endothelial growth factor A Mus musculus 49-85 27930695-8 2016 DHI administration upregulated the expression of vascular endothelial growth factor A (VEGF-A) and VEGF receptor-2 (VEGFR-2) in ischemic muscle. dehydrosoyasaponin I 0-3 vascular endothelial growth factor A Mus musculus 87-93 27930695-8 2016 DHI administration upregulated the expression of vascular endothelial growth factor A (VEGF-A) and VEGF receptor-2 (VEGFR-2) in ischemic muscle. dehydrosoyasaponin I 0-3 kinase insert domain protein receptor Mus musculus 99-114 27930695-8 2016 DHI administration upregulated the expression of vascular endothelial growth factor A (VEGF-A) and VEGF receptor-2 (VEGFR-2) in ischemic muscle. dehydrosoyasaponin I 0-3 kinase insert domain protein receptor Mus musculus 116-123 27930695-10 2016 We confirmed that upregulation of VEGF-A/VEGFR-2 by DHI promoted PPARdelta gene expression in both type 2 diabetic mice. dehydrosoyasaponin I 52-55 vascular endothelial growth factor A Mus musculus 34-40 27930695-10 2016 We confirmed that upregulation of VEGF-A/VEGFR-2 by DHI promoted PPARdelta gene expression in both type 2 diabetic mice. dehydrosoyasaponin I 52-55 kinase insert domain protein receptor Mus musculus 41-48 27930695-10 2016 We confirmed that upregulation of VEGF-A/VEGFR-2 by DHI promoted PPARdelta gene expression in both type 2 diabetic mice. dehydrosoyasaponin I 52-55 peroxisome proliferator activator receptor delta Mus musculus 65-74 27930695-11 2016 Our findings demonstrated that a multi-component Chinese medicine DHI effectively increased blood flow recovery after tissue ischemia in diabetic mice by promoting angiogenesis and improving glucose tolerance through a concomitant activation of VEGF-A/VEGFR-2 and PPARdelta signaling pathways. dehydrosoyasaponin I 66-69 vascular endothelial growth factor A Mus musculus 245-251 27930695-11 2016 Our findings demonstrated that a multi-component Chinese medicine DHI effectively increased blood flow recovery after tissue ischemia in diabetic mice by promoting angiogenesis and improving glucose tolerance through a concomitant activation of VEGF-A/VEGFR-2 and PPARdelta signaling pathways. dehydrosoyasaponin I 66-69 kinase insert domain protein receptor Mus musculus 252-259 27930695-11 2016 Our findings demonstrated that a multi-component Chinese medicine DHI effectively increased blood flow recovery after tissue ischemia in diabetic mice by promoting angiogenesis and improving glucose tolerance through a concomitant activation of VEGF-A/VEGFR-2 and PPARdelta signaling pathways. dehydrosoyasaponin I 66-69 peroxisome proliferator activator receptor delta Mus musculus 264-273 27677331-9 2016 Moreover, to more specifically evaluate the DHI binding interactions, we employed molecular docking calculations, which suggested binding near the hydrophobic site of Cys-1-Cys-122 residues. dehydrosoyasaponin I 44-47 cystin 1 Homo sapiens 167-172 26970569-8 2016 DHI decreased ISO-induced atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) elevation both at the mRNA and protein levels (p<0.05 and p<0.01, respectively). dehydrosoyasaponin I 0-3 natriuretic peptide B Rattus norvegicus 63-88 27071688-5 2016 The validity of DHI total, 5-item and 2-item questionnaires to screen for BPPV was assessed by receiver operating characteristic (ROC) curves. dehydrosoyasaponin I 16-19 benign paroxysmal positional vertigo Homo sapiens 74-78 27071688-7 2016 Area under the curve of total DHI, 5-item and 2-item scores for discriminating BPPV from those without was 0.678 (95 % CI 0.578-0.778), 0.873(95 % CI 0.807-0.940) and 0.895(95 % CI 0.836-0.953), respectively. dehydrosoyasaponin I 30-33 benign paroxysmal positional vertigo Homo sapiens 79-83 27071688-10 2016 The present study indicated that both 5-item and 2-item questionnaires in the Chinese version of DHI may be more valid than DHI total score for screening objective BPPV and merit further application in clinical practice in China. dehydrosoyasaponin I 97-100 benign paroxysmal positional vertigo Homo sapiens 164-168 27431009-6 2016 Results indicated that pre-B-cell leukemia transcription factor 1 and cyclic AMP-dependent transcription factor 1, along with six other TFs, are putative target TFs for DHI-mediated protection against cerebral ischemia. dehydrosoyasaponin I 169-172 PBX homeobox 1 Homo sapiens 23-113 27107944-6 2016 Besides, DHI had the same protective effects with conivaptan, a dual vasopressin V1A and V2 receptor antagonist, in reducing the RCM damage induced by overdose AVP. dehydrosoyasaponin I 9-12 arginine vasopressin Rattus norvegicus 160-163 27107944-8 2016 Meanwhile, the AVP level was elevated dramatically in OGD and reperfusion PRNCs, and DHI was able to decrease the AVP expression in the injured PRNCs. dehydrosoyasaponin I 85-88 arginine vasopressin Rattus norvegicus 114-117 27107944-10 2016 The ability of DHI to reinstate AVP level may be one of the mechanisms of its brain and heart co-protection effects. dehydrosoyasaponin I 15-18 arginine vasopressin Rattus norvegicus 32-35 26970569-8 2016 DHI decreased ISO-induced atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) elevation both at the mRNA and protein levels (p<0.05 and p<0.01, respectively). dehydrosoyasaponin I 0-3 natriuretic peptide B Rattus norvegicus 90-93 26970569-9 2016 Western blot showed that DHI down-regulated the phosphorylation of p38. dehydrosoyasaponin I 25-28 mitogen activated protein kinase 14 Rattus norvegicus 67-70 26970569-12 2016 CONCLUSION: These data demonstrate that DHI might exert anti-cardiac hypertrophic effects by regulating p38 and NF-kappab pathway. dehydrosoyasaponin I 40-43 mitogen activated protein kinase 14 Rattus norvegicus 104-107 26061387-7 2015 In retinas, DHI blocked the shrink of whole retina and retinal sub-layers by inhibiting expression of caspase 3, matrix metalloproteinase 2 (MMP-2) and MMP-9, accumulation of carbohydrate macromolecules and formation of acellular capillaries. dehydrosoyasaponin I 12-15 caspase 3 Mus musculus 102-111 27161407-16 2016 DHI strengthened the inhibition activity of ASA on both COX-1 and COX-2, which showed that DHI alleviated ASA induced gastric mucosal damage but not antagonized anti-COX effect of ASA. dehydrosoyasaponin I 0-3 cytochrome c oxidase I, mitochondrial Rattus norvegicus 56-61 27161407-16 2016 DHI strengthened the inhibition activity of ASA on both COX-1 and COX-2, which showed that DHI alleviated ASA induced gastric mucosal damage but not antagonized anti-COX effect of ASA. dehydrosoyasaponin I 0-3 cytochrome c oxidase II, mitochondrial Rattus norvegicus 66-71 27161407-16 2016 DHI strengthened the inhibition activity of ASA on both COX-1 and COX-2, which showed that DHI alleviated ASA induced gastric mucosal damage but not antagonized anti-COX effect of ASA. dehydrosoyasaponin I 91-94 cytochrome c oxidase I, mitochondrial Rattus norvegicus 56-61 27161407-16 2016 DHI strengthened the inhibition activity of ASA on both COX-1 and COX-2, which showed that DHI alleviated ASA induced gastric mucosal damage but not antagonized anti-COX effect of ASA. dehydrosoyasaponin I 91-94 cytochrome c oxidase II, mitochondrial Rattus norvegicus 66-71 26290634-10 2015 Moreover, DHI (3 g/kg) remarkably decreased LPS-induced protein expression of TNF-alpha (340.55 +- 10.18 for 3 g/kg, P < 0.01), IL-6 (261.34 +- 10.18 for 3 g/kg, P < 0.01), and enzyme activity of caspase-3 (0.93 +- 0.029 for 3 g/kg, P < 0.01). dehydrosoyasaponin I 10-13 tumor necrosis factor Mus musculus 78-87 26290634-10 2015 Moreover, DHI (3 g/kg) remarkably decreased LPS-induced protein expression of TNF-alpha (340.55 +- 10.18 for 3 g/kg, P < 0.01), IL-6 (261.34 +- 10.18 for 3 g/kg, P < 0.01), and enzyme activity of caspase-3 (0.93 +- 0.029 for 3 g/kg, P < 0.01). dehydrosoyasaponin I 10-13 interleukin 6 Mus musculus 131-135 26290634-10 2015 Moreover, DHI (3 g/kg) remarkably decreased LPS-induced protein expression of TNF-alpha (340.55 +- 10.18 for 3 g/kg, P < 0.01), IL-6 (261.34 +- 10.18 for 3 g/kg, P < 0.01), and enzyme activity of caspase-3 (0.93 +- 0.029 for 3 g/kg, P < 0.01). dehydrosoyasaponin I 10-13 caspase 3 Mus musculus 202-211 26290634-11 2015 The LPS-induced mRNA expression of TNF-alpha, IL-6 and caspase-3 was also decreased by DHI. dehydrosoyasaponin I 87-90 tumor necrosis factor Mus musculus 35-44 26290634-11 2015 The LPS-induced mRNA expression of TNF-alpha, IL-6 and caspase-3 was also decreased by DHI. dehydrosoyasaponin I 87-90 interleukin 6 Mus musculus 46-50 26290634-11 2015 The LPS-induced mRNA expression of TNF-alpha, IL-6 and caspase-3 was also decreased by DHI. dehydrosoyasaponin I 87-90 caspase 3 Mus musculus 55-64 26290634-12 2015 Western blot analysis revealed that DHI antagonised LPS-stimulated decrease of Bcl-2 and increase of Bax protein expression. dehydrosoyasaponin I 36-39 B cell leukemia/lymphoma 2 Mus musculus 79-84 26290634-12 2015 Western blot analysis revealed that DHI antagonised LPS-stimulated decrease of Bcl-2 and increase of Bax protein expression. dehydrosoyasaponin I 36-39 BCL2-associated X protein Mus musculus 101-104 26290634-13 2015 Furthermore, DHI inhibited LPS-induced IkappaBalpha and NF-kappaB p65 phosphorylation. dehydrosoyasaponin I 13-16 nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha Mus musculus 39-51 26290634-13 2015 Furthermore, DHI inhibited LPS-induced IkappaBalpha and NF-kappaB p65 phosphorylation. dehydrosoyasaponin I 13-16 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 56-65 26290634-13 2015 Furthermore, DHI inhibited LPS-induced IkappaBalpha and NF-kappaB p65 phosphorylation. dehydrosoyasaponin I 13-16 v-rel reticuloendotheliosis viral oncogene homolog A (avian) Mus musculus 66-69 26061387-7 2015 In retinas, DHI blocked the shrink of whole retina and retinal sub-layers by inhibiting expression of caspase 3, matrix metalloproteinase 2 (MMP-2) and MMP-9, accumulation of carbohydrate macromolecules and formation of acellular capillaries. dehydrosoyasaponin I 12-15 matrix metallopeptidase 2 Mus musculus 113-139 26061387-7 2015 In retinas, DHI blocked the shrink of whole retina and retinal sub-layers by inhibiting expression of caspase 3, matrix metalloproteinase 2 (MMP-2) and MMP-9, accumulation of carbohydrate macromolecules and formation of acellular capillaries. dehydrosoyasaponin I 12-15 matrix metallopeptidase 2 Mus musculus 141-146 26061387-7 2015 In retinas, DHI blocked the shrink of whole retina and retinal sub-layers by inhibiting expression of caspase 3, matrix metalloproteinase 2 (MMP-2) and MMP-9, accumulation of carbohydrate macromolecules and formation of acellular capillaries. dehydrosoyasaponin I 12-15 matrix metallopeptidase 9 Mus musculus 152-157 26061387-8 2015 DHI improved renal functions by inhibiting mesangial matrix expansion, expression of vascular endothelial growth factor A, fibronectin and advanced glycation end products in kidneys. dehydrosoyasaponin I 0-3 vascular endothelial growth factor A Mus musculus 85-121 26061387-8 2015 DHI improved renal functions by inhibiting mesangial matrix expansion, expression of vascular endothelial growth factor A, fibronectin and advanced glycation end products in kidneys. dehydrosoyasaponin I 0-3 fibronectin 1 Mus musculus 123-134 26061387-9 2015 Mechanistically, DHI induced expression of glucokinase, AMPKalpha/phosphorylated AMPKalpha, insulin receptor substrate 1, fibroblast growth factor 21 and peroxisome proliferator-activated gamma. dehydrosoyasaponin I 17-20 glucokinase Mus musculus 43-54 26061387-9 2015 Mechanistically, DHI induced expression of glucokinase, AMPKalpha/phosphorylated AMPKalpha, insulin receptor substrate 1, fibroblast growth factor 21 and peroxisome proliferator-activated gamma. dehydrosoyasaponin I 17-20 insulin receptor substrate 1 Mus musculus 92-120 26061387-9 2015 Mechanistically, DHI induced expression of glucokinase, AMPKalpha/phosphorylated AMPKalpha, insulin receptor substrate 1, fibroblast growth factor 21 and peroxisome proliferator-activated gamma. dehydrosoyasaponin I 17-20 fibroblast growth factor 21 Mus musculus 122-149 26035712-2 2015 The bindings of eight natural components in DHI between bovine serum albumin (BSA) were studied by fluorescence spectroscopy technology and molecular docking. dehydrosoyasaponin I 44-47 albumin Homo sapiens 63-76 26035712-8 2015 The participation of these natural components in DHI affected the interaction between the components of the SaB-BSA system. dehydrosoyasaponin I 49-52 SH3 domain binding protein 5 Homo sapiens 108-111 26035712-9 2015 Therefore, when DHI is used in mammals, SaB is released from serum albumin more quickly than it is used alone. dehydrosoyasaponin I 16-19 SH3 domain binding protein 5 Homo sapiens 40-43 26035712-9 2015 Therefore, when DHI is used in mammals, SaB is released from serum albumin more quickly than it is used alone. dehydrosoyasaponin I 16-19 albumin Homo sapiens 61-74 25664126-4 2014 There was a major change in PON1 activity, SOD and MDA after 4 weeks DHI treatment (P < 0.05). dehydrosoyasaponin I 69-72 paraoxonase 1 Homo sapiens 28-32 25664126-4 2014 There was a major change in PON1 activity, SOD and MDA after 4 weeks DHI treatment (P < 0.05). dehydrosoyasaponin I 69-72 superoxide dismutase 1 Homo sapiens 43-46 25664126-7 2014 DHI can raise serum PON1, SOD activity and lower MDA to improve the antioxidant effect in elderly patients with coronary heart disease. dehydrosoyasaponin I 0-3 paraoxonase 1 Homo sapiens 20-24 25333388-4 2014 Targeted-covalent inhibitors based on the weakly electrophilic 3-bromo-4,5-dihydroisoxazole (DHI) scaffold have been widely used to study TG2 biology and are well tolerated in vivo, but these compounds have only modest potency, and their selectivity toward other transglutaminase homologues is largely unknown. dehydrosoyasaponin I 93-96 transglutaminase 2 Homo sapiens 138-141 25664126-7 2014 DHI can raise serum PON1, SOD activity and lower MDA to improve the antioxidant effect in elderly patients with coronary heart disease. dehydrosoyasaponin I 0-3 superoxide dismutase 1 Homo sapiens 26-29 23840272-5 2013 These 3 compounds and DHI all decreased the levels of IL-1, TNF- alpha , and MDA, increased those of IL-10 and SOD activity in vivo and in vitro, and had antiapoptotic effects, as shown by flow cytometric analysis and TUNEL assay. dehydrosoyasaponin I 22-25 tumor necrosis factor Homo sapiens 60-70 24803317-5 2014 We observed that DHI inhibited lesions in both Apoe-/- and Ldlr-/- mice. dehydrosoyasaponin I 17-20 apolipoprotein E Mus musculus 47-51 24803317-5 2014 We observed that DHI inhibited lesions in both Apoe-/- and Ldlr-/- mice. dehydrosoyasaponin I 17-20 low density lipoprotein receptor Mus musculus 59-63 24803317-7 2014 Although DHI reduced HMG-CoA reductase messenger RNA expression in both female Apoe-/- and Ldlr-/- mice, it decreased low-density lipoprotein cholesterol levels only in female Apoe-/- mice. dehydrosoyasaponin I 9-12 apolipoprotein E Mus musculus 79-83 24803317-7 2014 Although DHI reduced HMG-CoA reductase messenger RNA expression in both female Apoe-/- and Ldlr-/- mice, it decreased low-density lipoprotein cholesterol levels only in female Apoe-/- mice. dehydrosoyasaponin I 9-12 low density lipoprotein receptor Mus musculus 91-95 24803317-7 2014 Although DHI reduced HMG-CoA reductase messenger RNA expression in both female Apoe-/- and Ldlr-/- mice, it decreased low-density lipoprotein cholesterol levels only in female Apoe-/- mice. dehydrosoyasaponin I 9-12 apolipoprotein E Mus musculus 176-180 24803317-8 2014 In addition to attenuation of lipopolysaccharide-induced expression of TNF-alpha, IL-1beta, IL-6 in macrophages, and human C-reactive protein in hepatocytes, respectively, at the transcriptional level in vitro, DHI also reduced TNF-alpha protein expression in aortic root of both Apoe-/- and Ldlr-/- mice, suggesting the importance of the anti-inflammatory properties of DHI in the inhibition of lesion development. dehydrosoyasaponin I 211-214 tumor necrosis factor Homo sapiens 71-80 24803317-8 2014 In addition to attenuation of lipopolysaccharide-induced expression of TNF-alpha, IL-1beta, IL-6 in macrophages, and human C-reactive protein in hepatocytes, respectively, at the transcriptional level in vitro, DHI also reduced TNF-alpha protein expression in aortic root of both Apoe-/- and Ldlr-/- mice, suggesting the importance of the anti-inflammatory properties of DHI in the inhibition of lesion development. dehydrosoyasaponin I 211-214 interleukin 1 beta Homo sapiens 82-90 24803317-8 2014 In addition to attenuation of lipopolysaccharide-induced expression of TNF-alpha, IL-1beta, IL-6 in macrophages, and human C-reactive protein in hepatocytes, respectively, at the transcriptional level in vitro, DHI also reduced TNF-alpha protein expression in aortic root of both Apoe-/- and Ldlr-/- mice, suggesting the importance of the anti-inflammatory properties of DHI in the inhibition of lesion development. dehydrosoyasaponin I 211-214 interleukin 6 Homo sapiens 92-96 24803317-8 2014 In addition to attenuation of lipopolysaccharide-induced expression of TNF-alpha, IL-1beta, IL-6 in macrophages, and human C-reactive protein in hepatocytes, respectively, at the transcriptional level in vitro, DHI also reduced TNF-alpha protein expression in aortic root of both Apoe-/- and Ldlr-/- mice, suggesting the importance of the anti-inflammatory properties of DHI in the inhibition of lesion development. dehydrosoyasaponin I 211-214 C-reactive protein Homo sapiens 123-141 24803317-8 2014 In addition to attenuation of lipopolysaccharide-induced expression of TNF-alpha, IL-1beta, IL-6 in macrophages, and human C-reactive protein in hepatocytes, respectively, at the transcriptional level in vitro, DHI also reduced TNF-alpha protein expression in aortic root of both Apoe-/- and Ldlr-/- mice, suggesting the importance of the anti-inflammatory properties of DHI in the inhibition of lesion development. dehydrosoyasaponin I 371-374 tumor necrosis factor Homo sapiens 71-80 24803317-8 2014 In addition to attenuation of lipopolysaccharide-induced expression of TNF-alpha, IL-1beta, IL-6 in macrophages, and human C-reactive protein in hepatocytes, respectively, at the transcriptional level in vitro, DHI also reduced TNF-alpha protein expression in aortic root of both Apoe-/- and Ldlr-/- mice, suggesting the importance of the anti-inflammatory properties of DHI in the inhibition of lesion development. dehydrosoyasaponin I 371-374 interleukin 1 beta Homo sapiens 82-90 24803317-8 2014 In addition to attenuation of lipopolysaccharide-induced expression of TNF-alpha, IL-1beta, IL-6 in macrophages, and human C-reactive protein in hepatocytes, respectively, at the transcriptional level in vitro, DHI also reduced TNF-alpha protein expression in aortic root of both Apoe-/- and Ldlr-/- mice, suggesting the importance of the anti-inflammatory properties of DHI in the inhibition of lesion development. dehydrosoyasaponin I 371-374 interleukin 6 Homo sapiens 92-96 24803317-8 2014 In addition to attenuation of lipopolysaccharide-induced expression of TNF-alpha, IL-1beta, IL-6 in macrophages, and human C-reactive protein in hepatocytes, respectively, at the transcriptional level in vitro, DHI also reduced TNF-alpha protein expression in aortic root of both Apoe-/- and Ldlr-/- mice, suggesting the importance of the anti-inflammatory properties of DHI in the inhibition of lesion development. dehydrosoyasaponin I 371-374 C-reactive protein Homo sapiens 123-141 24772178-6 2014 We found that mice administrated with DHI displayed a higher survival rate, lower serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), glutathione S-transferase (GST), and tumor necrosis factor (TNF)- alpha . dehydrosoyasaponin I 38-41 glutamic pyruvic transaminase, soluble Mus musculus 98-122 24772178-6 2014 We found that mice administrated with DHI displayed a higher survival rate, lower serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), glutathione S-transferase (GST), and tumor necrosis factor (TNF)- alpha . dehydrosoyasaponin I 38-41 glutamic pyruvic transaminase, soluble Mus musculus 124-127 24772178-6 2014 We found that mice administrated with DHI displayed a higher survival rate, lower serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), glutathione S-transferase (GST), and tumor necrosis factor (TNF)- alpha . dehydrosoyasaponin I 38-41 solute carrier family 17 (anion/sugar transporter), member 5 Mus musculus 130-156 24772178-6 2014 We found that mice administrated with DHI displayed a higher survival rate, lower serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), glutathione S-transferase (GST), and tumor necrosis factor (TNF)- alpha . dehydrosoyasaponin I 38-41 solute carrier family 17 (anion/sugar transporter), member 5 Mus musculus 158-161 24772178-6 2014 We found that mice administrated with DHI displayed a higher survival rate, lower serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), glutathione S-transferase (GST), and tumor necrosis factor (TNF)- alpha . dehydrosoyasaponin I 38-41 hematopoietic prostaglandin D synthase Mus musculus 188-213 24772178-6 2014 We found that mice administrated with DHI displayed a higher survival rate, lower serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), glutathione S-transferase (GST), and tumor necrosis factor (TNF)- alpha . dehydrosoyasaponin I 38-41 hematopoietic prostaglandin D synthase Mus musculus 215-218 24772178-6 2014 We found that mice administrated with DHI displayed a higher survival rate, lower serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), glutathione S-transferase (GST), and tumor necrosis factor (TNF)- alpha . dehydrosoyasaponin I 38-41 tumor necrosis factor Mus musculus 225-259 24772178-7 2014 DHI inhibited the elevations of hepatic lipid peroxidation (malondialdehyde), caspase-8 activity, and mRNA expression levels of inflammatory cytokines (interleukin-1 beta and interleukin-6) increased by D-GalN/LPS in the liver. dehydrosoyasaponin I 0-3 caspase 8 Mus musculus 78-87 24772178-7 2014 DHI inhibited the elevations of hepatic lipid peroxidation (malondialdehyde), caspase-8 activity, and mRNA expression levels of inflammatory cytokines (interleukin-1 beta and interleukin-6) increased by D-GalN/LPS in the liver. dehydrosoyasaponin I 0-3 interleukin 1 beta Mus musculus 152-170 24772178-7 2014 DHI inhibited the elevations of hepatic lipid peroxidation (malondialdehyde), caspase-8 activity, and mRNA expression levels of inflammatory cytokines (interleukin-1 beta and interleukin-6) increased by D-GalN/LPS in the liver. dehydrosoyasaponin I 0-3 interleukin 6 Mus musculus 175-188 23921303-6 2013 DHI-mediated endothelial-dependent vasorelaxation was independent on nitric oxide/endothelial nitric oxide synthase but was via prostacyclin pathway by increasing cyclooxygenase (COX)-2 gene expression and prostacyclin production. dehydrosoyasaponin I 0-3 cytochrome c oxidase II, mitochondrial Rattus norvegicus 163-185 23954279-15 2013 Meanwhile, the mRNA expressions of iNOS, IL-6, IL-1beta, MCP-1 in mice liver and kidney were significantly reduced by DHI. dehydrosoyasaponin I 118-121 nitric oxide synthase 2, inducible Mus musculus 35-39 23954279-15 2013 Meanwhile, the mRNA expressions of iNOS, IL-6, IL-1beta, MCP-1 in mice liver and kidney were significantly reduced by DHI. dehydrosoyasaponin I 118-121 interleukin 6 Mus musculus 41-45 23954279-15 2013 Meanwhile, the mRNA expressions of iNOS, IL-6, IL-1beta, MCP-1 in mice liver and kidney were significantly reduced by DHI. dehydrosoyasaponin I 118-121 interleukin 1 beta Mus musculus 47-55 23954279-15 2013 Meanwhile, the mRNA expressions of iNOS, IL-6, IL-1beta, MCP-1 in mice liver and kidney were significantly reduced by DHI. dehydrosoyasaponin I 118-121 chemokine (C-C motif) ligand 2 Mus musculus 57-62 23954279-16 2013 Experiments performed in vitro further revealed that the productions of NO, PGE2 and the mRNA expressions of iNOS, COX-2 were notably inhibited by DHI. dehydrosoyasaponin I 147-150 nitric oxide synthase 2, inducible Mus musculus 109-113 23954279-16 2013 Experiments performed in vitro further revealed that the productions of NO, PGE2 and the mRNA expressions of iNOS, COX-2 were notably inhibited by DHI. dehydrosoyasaponin I 147-150 cytochrome c oxidase II, mitochondrial Mus musculus 115-120 23954279-17 2013 Cell-based ELISA revealed that the COX-2 protein expression was diminished by DHI. dehydrosoyasaponin I 78-81 cytochrome c oxidase II, mitochondrial Mus musculus 35-40 23954279-18 2013 The results of ELISA demonstrated that DHI significantly down-regulated the protein productions of IL-6 and MCP-1. dehydrosoyasaponin I 39-42 interleukin 6 Mus musculus 99-103 23954279-18 2013 The results of ELISA demonstrated that DHI significantly down-regulated the protein productions of IL-6 and MCP-1. dehydrosoyasaponin I 39-42 chemokine (C-C motif) ligand 2 Mus musculus 108-113 23954279-19 2013 Furthermore, the mRNA expressions of iNOS, COX-2, TNF-alpha, IL-1beta, IL-6 and MCP-1 analyzed by real-time RT-PCR were suppressed by DHI. dehydrosoyasaponin I 134-137 nitric oxide synthase 2, inducible Mus musculus 37-41 23954279-19 2013 Furthermore, the mRNA expressions of iNOS, COX-2, TNF-alpha, IL-1beta, IL-6 and MCP-1 analyzed by real-time RT-PCR were suppressed by DHI. dehydrosoyasaponin I 134-137 cytochrome c oxidase II, mitochondrial Mus musculus 43-48 23954279-19 2013 Furthermore, the mRNA expressions of iNOS, COX-2, TNF-alpha, IL-1beta, IL-6 and MCP-1 analyzed by real-time RT-PCR were suppressed by DHI. dehydrosoyasaponin I 134-137 tumor necrosis factor Mus musculus 50-59 23954279-19 2013 Furthermore, the mRNA expressions of iNOS, COX-2, TNF-alpha, IL-1beta, IL-6 and MCP-1 analyzed by real-time RT-PCR were suppressed by DHI. dehydrosoyasaponin I 134-137 interleukin 1 beta Mus musculus 61-69 23954279-19 2013 Furthermore, the mRNA expressions of iNOS, COX-2, TNF-alpha, IL-1beta, IL-6 and MCP-1 analyzed by real-time RT-PCR were suppressed by DHI. dehydrosoyasaponin I 134-137 interleukin 6 Mus musculus 71-75 23954279-19 2013 Furthermore, the mRNA expressions of iNOS, COX-2, TNF-alpha, IL-1beta, IL-6 and MCP-1 analyzed by real-time RT-PCR were suppressed by DHI. dehydrosoyasaponin I 134-137 chemokine (C-C motif) ligand 2 Mus musculus 80-85 23954279-20 2013 CONCLUSIONS: These results demonstrate that DHI exerts the protective effect through inhibiting the expressions of iNOS, COX-2, IL-1beta, IL-6, MCP-1 and TNF-alpha, which elucidate that DHI may be a strongly multi-target Chinese medicine injection on improving the inflammatory diseases. dehydrosoyasaponin I 44-47 nitric oxide synthase 2, inducible Mus musculus 115-119 23954279-20 2013 CONCLUSIONS: These results demonstrate that DHI exerts the protective effect through inhibiting the expressions of iNOS, COX-2, IL-1beta, IL-6, MCP-1 and TNF-alpha, which elucidate that DHI may be a strongly multi-target Chinese medicine injection on improving the inflammatory diseases. dehydrosoyasaponin I 44-47 cytochrome c oxidase II, mitochondrial Mus musculus 121-126 23954279-20 2013 CONCLUSIONS: These results demonstrate that DHI exerts the protective effect through inhibiting the expressions of iNOS, COX-2, IL-1beta, IL-6, MCP-1 and TNF-alpha, which elucidate that DHI may be a strongly multi-target Chinese medicine injection on improving the inflammatory diseases. dehydrosoyasaponin I 44-47 interleukin 1 beta Mus musculus 128-136 23954279-20 2013 CONCLUSIONS: These results demonstrate that DHI exerts the protective effect through inhibiting the expressions of iNOS, COX-2, IL-1beta, IL-6, MCP-1 and TNF-alpha, which elucidate that DHI may be a strongly multi-target Chinese medicine injection on improving the inflammatory diseases. dehydrosoyasaponin I 44-47 interleukin 6 Mus musculus 138-142 23954279-20 2013 CONCLUSIONS: These results demonstrate that DHI exerts the protective effect through inhibiting the expressions of iNOS, COX-2, IL-1beta, IL-6, MCP-1 and TNF-alpha, which elucidate that DHI may be a strongly multi-target Chinese medicine injection on improving the inflammatory diseases. dehydrosoyasaponin I 44-47 chemokine (C-C motif) ligand 2 Mus musculus 144-149 23954279-20 2013 CONCLUSIONS: These results demonstrate that DHI exerts the protective effect through inhibiting the expressions of iNOS, COX-2, IL-1beta, IL-6, MCP-1 and TNF-alpha, which elucidate that DHI may be a strongly multi-target Chinese medicine injection on improving the inflammatory diseases. dehydrosoyasaponin I 44-47 tumor necrosis factor Mus musculus 154-163 23954279-20 2013 CONCLUSIONS: These results demonstrate that DHI exerts the protective effect through inhibiting the expressions of iNOS, COX-2, IL-1beta, IL-6, MCP-1 and TNF-alpha, which elucidate that DHI may be a strongly multi-target Chinese medicine injection on improving the inflammatory diseases. dehydrosoyasaponin I 186-189 nitric oxide synthase 2, inducible Mus musculus 115-119 23850708-7 2013 RESULTS: In LPS challenged mice, DHI significantly reduced the infiltration of activated neutrophils and decreased the levels of TNF-alpha and IL-6 in bronchoalveolar lavage fluid (BALF). dehydrosoyasaponin I 33-36 tumor necrosis factor Mus musculus 129-138 23850708-7 2013 RESULTS: In LPS challenged mice, DHI significantly reduced the infiltration of activated neutrophils and decreased the levels of TNF-alpha and IL-6 in bronchoalveolar lavage fluid (BALF). dehydrosoyasaponin I 33-36 interleukin 6 Mus musculus 143-147 23850708-9 2013 In addition, DHI markedly prevented LPS-induced elevation of MDA and MPO levels, as well as reduction of SOD activity. dehydrosoyasaponin I 13-16 myeloperoxidase Mus musculus 69-72 24047947-15 2013 CONCLUSIONS: The results of the study indicated that individuals with both objective and subjective BPPV demonstrated significant improvement in DHI scores following CRM treatment. dehydrosoyasaponin I 145-148 benign paroxysmal positional vertigo Homo sapiens 100-104 24024337-5 2013 Cells that received ox-LDL and 3 mL/L DHI possessed higher MSR1 mRNA levels than the controls, whereas cells treated with ox-LDL and higher DHI concentrations (10, 30 or 60 mL/L) showed lower MSR1 expression levels (but the differences observed between DHI concentration groups were not statistically significant, P > 0.05). dehydrosoyasaponin I 38-41 macrophage scavenger receptor 1 Homo sapiens 59-63 24024337-6 2013 ABCA1 expression in cells treated with ox-LDL and 3, 10 or 30 mL/L DHI was higher than in the control cells, and increased with increasing DHI concentration (P < 0.05). dehydrosoyasaponin I 67-70 ATP binding cassette subfamily A member 1 Homo sapiens 0-5 24024337-6 2013 ABCA1 expression in cells treated with ox-LDL and 3, 10 or 30 mL/L DHI was higher than in the control cells, and increased with increasing DHI concentration (P < 0.05). dehydrosoyasaponin I 139-142 ATP binding cassette subfamily A member 1 Homo sapiens 0-5 24024337-7 2013 ABCA1 expression in cells treated with ox-LDL and the highest DHI concentration tested (60 mL/L) was not significantly different from that in the controls. dehydrosoyasaponin I 62-65 ATP binding cassette subfamily A member 1 Homo sapiens 0-5 24024337-8 2013 ABCA1 mRNA levels in cells treated with ox-LDL and DHI were similar to, or lower than, those in cells treated with ox-LDL and the LXR agonist. dehydrosoyasaponin I 51-54 ATP binding cassette subfamily A member 1 Homo sapiens 0-5 24024337-10 2013 However, at certain concentrations (10 and 30 mL/L), DHI significantly increases ABCA1 mRNA levels. dehydrosoyasaponin I 53-56 ATP binding cassette subfamily A member 1 Homo sapiens 81-86 24024337-11 2013 Therefore, the anti-atherosclerotic action of DHI might be mediated by an increased expression of ABCA1. dehydrosoyasaponin I 46-49 ATP binding cassette subfamily A member 1 Homo sapiens 98-103 25317157-4 2014 Furthermore, DHI significantly reduced the permeability of the blood-brain barrier, increased occludin protein expression and decreased neutrophil infiltration, as well as profoundly suppressing the upregulation of matrix metallopeptidase-9 expression seen in rats that had received vehicle. dehydrosoyasaponin I 13-16 occludin Rattus norvegicus 94-102 25317157-4 2014 Furthermore, DHI significantly reduced the permeability of the blood-brain barrier, increased occludin protein expression and decreased neutrophil infiltration, as well as profoundly suppressing the upregulation of matrix metallopeptidase-9 expression seen in rats that had received vehicle. dehydrosoyasaponin I 13-16 matrix metallopeptidase 9 Rattus norvegicus 215-240 24803317-9 2014 Taken together, our study demonstrates that DHI inhibits atherosclerosis in both Apoe-/- and Ldlr-/- mice with various mechanisms, including anti-inflammation. dehydrosoyasaponin I 44-47 apolipoprotein E Mus musculus 81-85 24803317-9 2014 Taken together, our study demonstrates that DHI inhibits atherosclerosis in both Apoe-/- and Ldlr-/- mice with various mechanisms, including anti-inflammation. dehydrosoyasaponin I 44-47 low density lipoprotein receptor Mus musculus 93-97 23840272-5 2013 These 3 compounds and DHI all decreased the levels of IL-1, TNF- alpha , and MDA, increased those of IL-10 and SOD activity in vivo and in vitro, and had antiapoptotic effects, as shown by flow cytometric analysis and TUNEL assay. dehydrosoyasaponin I 22-25 interleukin 10 Homo sapiens 101-106 23840272-5 2013 These 3 compounds and DHI all decreased the levels of IL-1, TNF- alpha , and MDA, increased those of IL-10 and SOD activity in vivo and in vitro, and had antiapoptotic effects, as shown by flow cytometric analysis and TUNEL assay. dehydrosoyasaponin I 22-25 superoxide dismutase 1 Homo sapiens 111-114 22038191-8 2012 The P-CS group showed improvement in sensory nerve conduction velocity, distal latency, grip strength, and DHI parameters. dehydrosoyasaponin I 107-110 PCS Homo sapiens 4-8 23472142-10 2013 The association of DHI score >=50 with the BPPV was found to be statistically significant with x(2) value = 58.2 at P<0.01. dehydrosoyasaponin I 19-22 benign paroxysmal positional vertigo Homo sapiens 46-50 21434335-8 2011 CONCLUSIONS: Combined conventional therapy with DHI for 2 weeks can significantly reduce the plasma levels of ET-1, sP-sel and hs-CRP in ACS patients after PCI, suggesting that DHI has certain effects in protecting the endothelial function, inhibiting platelet activation and suppressing inflammatory reaction. dehydrosoyasaponin I 48-51 endothelin 1 Homo sapiens 110-114 22739234-5 2012 Similar to ciglitazone, a peroxisome proliferator activated receptor (PPAR) gamma agonist, DHI, could significantly reduce ox-LDL-induced expressions of mature markers, enhance the endocytotic function, and inhibit secretions of cytokine on DCs. dehydrosoyasaponin I 91-94 peroxisome proliferator activated receptor gamma Homo sapiens 70-74 22739234-6 2012 These effects of DHI could be partly reversed by silencing the PPARgamma. dehydrosoyasaponin I 17-20 peroxisome proliferator activated receptor gamma Homo sapiens 63-72 22739234-7 2012 In conclusion, DHI could inhibit ox-LDL-induced maturation of DCs partly through activating a PPARgamma-mediated signaling pathway. dehydrosoyasaponin I 15-18 peroxisome proliferator activated receptor gamma Homo sapiens 94-103 21434335-8 2011 CONCLUSIONS: Combined conventional therapy with DHI for 2 weeks can significantly reduce the plasma levels of ET-1, sP-sel and hs-CRP in ACS patients after PCI, suggesting that DHI has certain effects in protecting the endothelial function, inhibiting platelet activation and suppressing inflammatory reaction. dehydrosoyasaponin I 177-180 endothelin 1 Homo sapiens 110-114 19874874-3 2010 The results show that the highly selective GnRH agonist (i.e., [Des-Gly(10),d-His(Bzl)(6),Pro-NHEt(9)]-LHRH; Histrelin) stimulates the secretion of OT from an isolated rat H-N system. dehydrosoyasaponin I 76-81 gonadotropin releasing hormone 1 Rattus norvegicus 43-47 21180936-10 2010 Pre-treatment DHI results showed a significant impact of BPPV on quality of life. dehydrosoyasaponin I 14-17 benign paroxysmal positional vertigo Homo sapiens 57-61 20814074-3 2010 In this study we demonstrate, for the first time, that the highly selective GnRH agonist (i.e., [Des-Gly(10),D-His(Bzl)(6),Pro-NHEt(9)]-LHRH; histrelin) stimulates the release of VP from the rat H-N system, while native GnRH and its antagonist remain inactive in modifying this process in vitro. dehydrosoyasaponin I 109-114 gonadotropin releasing hormone 1 Rattus norvegicus 76-80 20814074-3 2010 In this study we demonstrate, for the first time, that the highly selective GnRH agonist (i.e., [Des-Gly(10),D-His(Bzl)(6),Pro-NHEt(9)]-LHRH; histrelin) stimulates the release of VP from the rat H-N system, while native GnRH and its antagonist remain inactive in modifying this process in vitro. dehydrosoyasaponin I 109-114 gonadotropin releasing hormone 1 Rattus norvegicus 220-224 20564561-6 2010 The catalytic efficiency of C. elegans DAO for D-Ser was substantially lower than that of human DAO, while the C. elegans DAO was more efficient at deamination of basic D-amino acids (D-Arg and D-His) than human DAO. dehydrosoyasaponin I 194-199 D-amino-acid oxidase Caenorhabditis elegans 39-42 20512546-6 2010 RESULTS: With FiF, the DHI is improved 7.0% and 5.7%, respectively (P < 0.0001) over the bilateral and lateral wedge CRT techniques. dehydrosoyasaponin I 23-26 apoptosis inhibitor 5 Homo sapiens 14-17 19926342-15 2010 At 2 weeks, the %DHI in the mice injected with Ad-GDF5 increased significantly compared with that of the mice injected with Ad-Luc; the increase was sustained for the rest of the experiment period. dehydrosoyasaponin I 17-20 growth differentiation factor 5 Mus musculus 50-54 18468678-0 2008 Effects of NPY and the specific Y1 receptor agonist [D-His(26)]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats. dehydrosoyasaponin I 53-58 neuropeptide Y Rattus norvegicus 64-67 18953097-3 2008 After icv injection of the NK-1 receptor antagonist--[(Tyr(6),D-Phe(7),D-His(9))-Substance P (6-11)]--the blood plasma OT concentration was significantly lower, when compared to vehicle-injected animals. dehydrosoyasaponin I 71-76 tachykinin receptor 1 Rattus norvegicus 27-40 19409630-10 2009 The sensitivity of a SCC threshold of 200,000 cells/mL for detection of subclinical IMI was 0.64, 0.69 and 0.65 for milk samples obtained at dry-off, post-calving and first DHI test, respectively. dehydrosoyasaponin I 173-176 SCC Bos taurus 21-24 19409630-13 2009 Cows with SCC greater than 200,000 cells/mL at both the last and the first DHI test between lactations produced 9.1 kg less milk on the first DHI test day than the average milk production of cows with SCC less than 200,000 cells/mL at both periods. dehydrosoyasaponin I 75-78 SCC Bos taurus 10-13 19409630-13 2009 Cows with SCC greater than 200,000 cells/mL at both the last and the first DHI test between lactations produced 9.1 kg less milk on the first DHI test day than the average milk production of cows with SCC less than 200,000 cells/mL at both periods. dehydrosoyasaponin I 142-145 SCC Bos taurus 10-13 18627905-2 2008 hCA III was efficiently activated by d-His, serotonin, pyridyl-alkylamines, and aminoethyl-piperazine/morpholine (K(A)s of 91nM-1.12microM), whereas the best hCA IV activators were 4-amino-phenylalanine, serotonin, and 4-(2-aminoethyl)-morpholine (K(A)s of 79nM-3.14microM). dehydrosoyasaponin I 37-42 carbonic anhydrase 3 Homo sapiens 0-7 18627905-2 2008 hCA III was efficiently activated by d-His, serotonin, pyridyl-alkylamines, and aminoethyl-piperazine/morpholine (K(A)s of 91nM-1.12microM), whereas the best hCA IV activators were 4-amino-phenylalanine, serotonin, and 4-(2-aminoethyl)-morpholine (K(A)s of 79nM-3.14microM). dehydrosoyasaponin I 37-42 HCA1 Homo sapiens 0-3 18468678-3 2008 The aim of the present experiments was to investigate the effects of NPY and the specific Y1 receptor agonist [D-His(26)]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats. dehydrosoyasaponin I 111-116 neuropeptide Y Rattus norvegicus 122-125 34538671-13 2022 Treatment with DHI reduced the in vitro phosphorylation levels of Src and STAT3, a transcription factor regulated by Src. dehydrosoyasaponin I 15-18 signal transducer and activator of transcription 3 Homo sapiens 74-79 16151354-7 2005 RESULTS: Individuals with BPPV had significantly higher mean scores on the newly developed BPPV subscale of the DHI (p < 0.01). dehydrosoyasaponin I 112-115 benign paroxysmal positional vertigo Homo sapiens 26-30 16151354-7 2005 RESULTS: Individuals with BPPV had significantly higher mean scores on the newly developed BPPV subscale of the DHI (p < 0.01). dehydrosoyasaponin I 112-115 benign paroxysmal positional vertigo Homo sapiens 91-95 16151354-10 2005 CONCLUSION: Items on the DHI appear to be helpful in determining the likelihood of an individual having the diagnosis of BPPV. dehydrosoyasaponin I 25-28 benign paroxysmal positional vertigo Homo sapiens 121-125 14507038-0 2003 The association between milk urea nitrogen and DHI production variables in western commercial dairy herds. dehydrosoyasaponin I 47-50 Weaning weight-maternal milk Bos taurus 24-28 9274145-0 1997 Fat/protein ratio in first DHI test milk as test for displaced abomasum in dairy cows. dehydrosoyasaponin I 27-30 FAT atypical cadherin 1 Bos taurus 0-3 9274145-0 1997 Fat/protein ratio in first DHI test milk as test for displaced abomasum in dairy cows. dehydrosoyasaponin I 27-30 Weaning weight-maternal milk Bos taurus 36-40 9274145-9 1997 The fat/protein ratio in first DHI test milk might be useful as a test for subsequent DA in dairy cows. dehydrosoyasaponin I 31-34 FAT atypical cadherin 1 Bos taurus 4-7 9274145-9 1997 The fat/protein ratio in first DHI test milk might be useful as a test for subsequent DA in dairy cows. dehydrosoyasaponin I 31-34 Weaning weight-maternal milk Bos taurus 40-44 7657740-4 1995 Each of six PCOS and six normal ovulatory women was administered a single s.c. injection of the GnRH agonist [(imBzl)D-His6, Pro9-NEt]-GnRH (D-His) at a dose of 0.01, 0.1, 1 and 10 micrograms/kg on four separate occasions. dehydrosoyasaponin I 117-122 gonadotropin releasing hormone 1 Homo sapiens 96-100 7657740-4 1995 Each of six PCOS and six normal ovulatory women was administered a single s.c. injection of the GnRH agonist [(imBzl)D-His6, Pro9-NEt]-GnRH (D-His) at a dose of 0.01, 0.1, 1 and 10 micrograms/kg on four separate occasions. dehydrosoyasaponin I 117-122 gonadotropin releasing hormone 1 Homo sapiens 135-139 8154929-4 1994 Indeed, when the melanin precursor molecule DHI(2C) is methylated by COMT it is no longer available for incorporation into melanin. dehydrosoyasaponin I 44-47 catechol-O-methyltransferase Homo sapiens 69-73 34538671-8 2022 The structural interaction of DHI with Src proteins was evaluated by molecular docking, molecular dynamics simulation, surface plasmon resonance imaging and Src kinase inhibition assay. dehydrosoyasaponin I 30-33 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 39-42 34538671-12 2022 We further identified and verified Src as a direct target of DHI by using molecular stimulation, surface plasmon resonance image and Src kinase inhibition assay. dehydrosoyasaponin I 61-64 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 35-38 34538671-13 2022 Treatment with DHI reduced the in vitro phosphorylation levels of Src and STAT3, a transcription factor regulated by Src. dehydrosoyasaponin I 15-18 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 66-69 16890434-1 2006 A novel series of C-3 urea, amide, and carbamate fused dihydroindazolocarbazole (DHI) analogs are reported as highly potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases with excellent cellular potency. dehydrosoyasaponin I 81-84 TEK receptor tyrosine kinase Rattus norvegicus 143-148 16890434-1 2006 A novel series of C-3 urea, amide, and carbamate fused dihydroindazolocarbazole (DHI) analogs are reported as highly potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases with excellent cellular potency. dehydrosoyasaponin I 81-84 kinase insert domain receptor Rattus norvegicus 153-160 12479971-7 2003 A significant antagonistic effect of [D-Phe(7), D-His(9)]SP (6-11), a selective antagonist for SP receptors, was observed against histamine-induced response. dehydrosoyasaponin I 48-53 tachykinin 1 Mus musculus 57-59 12479971-7 2003 A significant antagonistic effect of [D-Phe(7), D-His(9)]SP (6-11), a selective antagonist for SP receptors, was observed against histamine-induced response. dehydrosoyasaponin I 48-53 tachykinin 1 Mus musculus 95-97 9553715-9 1998 The protein/fat ratio in 1st DHI test milk may predict subsequent DA in dairy cows. dehydrosoyasaponin I 29-32 FAT atypical cadherin 1 Bos taurus 12-15 34785482-12 2022 Total DHI score demonstrated a moderate-to-strong association with HSAC (p = 0.30), VSAC (p = 0.32), and SP (p = 0.61). dehydrosoyasaponin I 6-9 adenylate cyclase 10 Homo sapiens 67-71 34538671-13 2022 Treatment with DHI reduced the in vitro phosphorylation levels of Src and STAT3, a transcription factor regulated by Src. dehydrosoyasaponin I 15-18 SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens 117-120 34538671-14 2022 In the xenograft mouse models, DHI dose-dependently suppressed tumor growth and Src and STAT3 phosphorylation. dehydrosoyasaponin I 31-34 Rous sarcoma oncogene Mus musculus 80-83 34538671-14 2022 In the xenograft mouse models, DHI dose-dependently suppressed tumor growth and Src and STAT3 phosphorylation. dehydrosoyasaponin I 31-34 signal transducer and activator of transcription 3 Mus musculus 88-93 34538671-15 2022 Moreover, Src overexpression partly abrogated the inhibitory effects of DHI on the proliferation and cell death in hepatoma cells. dehydrosoyasaponin I 72-75 Rous sarcoma oncogene Mus musculus 10-13 34538671-16 2022 CONCLUSION: Our results suggest that DHI inhibits the growth of hepatoma cells by direct inhibition of Src. dehydrosoyasaponin I 37-40 Rous sarcoma oncogene Mus musculus 103-106 34093718-14 2021 Conclusions: DQs is the predominant category of DHI and play an important role in antiapoptotic activity mediated by modulating PI3K-Akt signaling. dehydrosoyasaponin I 48-51 AKT serine/threonine kinase 1 Homo sapiens 133-136 34243610-6 2021 The results showed that under the treated with DHI, compared with OM, the formation of calcium nodules was reduced, and the expression of calcification-related markers Runx2 and OPN were down-regulated, which quantified by qRT-PCR and western blot. dehydrosoyasaponin I 47-50 RUNX family transcription factor 2 Homo sapiens 168-173 34243610-6 2021 The results showed that under the treated with DHI, compared with OM, the formation of calcium nodules was reduced, and the expression of calcification-related markers Runx2 and OPN were down-regulated, which quantified by qRT-PCR and western blot. dehydrosoyasaponin I 47-50 secreted phosphoprotein 1 Homo sapiens 178-181 34243610-7 2021 In addition, on the basis of OM induction, DHI also inhibited the phosphorylation of the NF-kappaB/ERK1/2 and SMAD1/5/8 signaling pathway. dehydrosoyasaponin I 43-46 nuclear factor kappa B subunit 1 Homo sapiens 89-98 34243610-7 2021 In addition, on the basis of OM induction, DHI also inhibited the phosphorylation of the NF-kappaB/ERK1/2 and SMAD1/5/8 signaling pathway. dehydrosoyasaponin I 43-46 mitogen-activated protein kinase 3 Homo sapiens 99-105 34243610-7 2021 In addition, on the basis of OM induction, DHI also inhibited the phosphorylation of the NF-kappaB/ERK1/2 and SMAD1/5/8 signaling pathway. dehydrosoyasaponin I 43-46 SMAD family member 1 Homo sapiens 110-119 34243610-8 2021 CONCLUSION: DHI (10 muM) treatment can reverse the osteogenic phenotypic transition of PVICs induced by osteogenic medium, and the mechanism may be related to NF-kappaB ERK 1/2 and Smad1/5/8 pathways. dehydrosoyasaponin I 12-15 nuclear factor kappa B subunit 1 Homo sapiens 159-168 34243610-8 2021 CONCLUSION: DHI (10 muM) treatment can reverse the osteogenic phenotypic transition of PVICs induced by osteogenic medium, and the mechanism may be related to NF-kappaB ERK 1/2 and Smad1/5/8 pathways. dehydrosoyasaponin I 12-15 mitogen-activated protein kinase 3 Homo sapiens 169-176 34243610-8 2021 CONCLUSION: DHI (10 muM) treatment can reverse the osteogenic phenotypic transition of PVICs induced by osteogenic medium, and the mechanism may be related to NF-kappaB ERK 1/2 and Smad1/5/8 pathways. dehydrosoyasaponin I 12-15 SMAD family member 1 Homo sapiens 181-190 34486420-7 2021 RESULTS: Tnmd-/-/Chm1-/- IVDs displayed increased DHI and histomorphological scores that indicated increased IVD degeneration compared to the WT and Tnmd-/- groups. dehydrosoyasaponin I 50-53 tenomodulin Mus musculus 9-13 35202715-12 2022 Reverse transcription-polymerase chain reaction showed that middle-dose DHI treatment significantly decreased SHC4 mRNA expression compared with that in the H/R group (P = 0.026), a finding consistent with our previous analysis of differentially expressed genes. dehydrosoyasaponin I 72-75 SHC adaptor protein 4 Homo sapiens 110-114 35080688-0 2022 DHI Increases the Proliferation and Migration of Schwann Cells Through the PI3K/AKT Pathway and the Expression of CXCL12 and GDNF to Promote Facial Nerve Function Repair. dehydrosoyasaponin I 0-3 AKT serine/threonine kinase 1 Rattus norvegicus 80-83 35080688-0 2022 DHI Increases the Proliferation and Migration of Schwann Cells Through the PI3K/AKT Pathway and the Expression of CXCL12 and GDNF to Promote Facial Nerve Function Repair. dehydrosoyasaponin I 0-3 C-X-C motif chemokine ligand 12 Rattus norvegicus 114-120 35080688-0 2022 DHI Increases the Proliferation and Migration of Schwann Cells Through the PI3K/AKT Pathway and the Expression of CXCL12 and GDNF to Promote Facial Nerve Function Repair. dehydrosoyasaponin I 0-3 glial cell derived neurotrophic factor Rattus norvegicus 125-129 35080688-5 2022 Our study found that DHI can promote the proliferation and migration of RSC96 cells, a Schwann cell line, and this effect is related to the activation of the PI3K/AKT pathway. dehydrosoyasaponin I 21-24 AKT serine/threonine kinase 1 Rattus norvegicus 163-166 35080688-7 2022 Further studies have found that DHI can also promote the expression of CXCL12 and GDNF at gene and protein levels, and CXCL12 is, while GDNF is not, PI3K/AKT pathway-dependent. dehydrosoyasaponin I 32-35 C-X-C motif chemokine ligand 12 Rattus norvegicus 71-77 35080688-7 2022 Further studies have found that DHI can also promote the expression of CXCL12 and GDNF at gene and protein levels, and CXCL12 is, while GDNF is not, PI3K/AKT pathway-dependent. dehydrosoyasaponin I 32-35 glial cell derived neurotrophic factor Rattus norvegicus 82-86 35080688-7 2022 Further studies have found that DHI can also promote the expression of CXCL12 and GDNF at gene and protein levels, and CXCL12 is, while GDNF is not, PI3K/AKT pathway-dependent. dehydrosoyasaponin I 32-35 C-X-C motif chemokine ligand 12 Rattus norvegicus 119-125 35080688-7 2022 Further studies have found that DHI can also promote the expression of CXCL12 and GDNF at gene and protein levels, and CXCL12 is, while GDNF is not, PI3K/AKT pathway-dependent. dehydrosoyasaponin I 32-35 glial cell derived neurotrophic factor Rattus norvegicus 136-140 35080688-7 2022 Further studies have found that DHI can also promote the expression of CXCL12 and GDNF at gene and protein levels, and CXCL12 is, while GDNF is not, PI3K/AKT pathway-dependent. dehydrosoyasaponin I 32-35 AKT serine/threonine kinase 1 Rattus norvegicus 154-157 35080688-8 2022 Animal experiments also confirmed that DHI could promote CXCL12 and GDNF expression and promote facial nerve function recovery and myelin regeneration. dehydrosoyasaponin I 39-42 C-X-C motif chemokine ligand 12 Rattus norvegicus 57-63 35080688-8 2022 Animal experiments also confirmed that DHI could promote CXCL12 and GDNF expression and promote facial nerve function recovery and myelin regeneration. dehydrosoyasaponin I 39-42 glial cell derived neurotrophic factor Rattus norvegicus 68-72 35080688-9 2022 In conclusion, our in vitro and in vivo experiments demonstrated that DHI could promote the proliferation and migration of Schwann cells through the PI3K/AKT pathway and increase the expression of CXCL12 and GDNF to promote facial nerve function repair. dehydrosoyasaponin I 70-73 AKT serine/threonine kinase 1 Rattus norvegicus 154-157 35080688-9 2022 In conclusion, our in vitro and in vivo experiments demonstrated that DHI could promote the proliferation and migration of Schwann cells through the PI3K/AKT pathway and increase the expression of CXCL12 and GDNF to promote facial nerve function repair. dehydrosoyasaponin I 70-73 C-X-C motif chemokine ligand 12 Rattus norvegicus 197-203 35080688-9 2022 In conclusion, our in vitro and in vivo experiments demonstrated that DHI could promote the proliferation and migration of Schwann cells through the PI3K/AKT pathway and increase the expression of CXCL12 and GDNF to promote facial nerve function repair. dehydrosoyasaponin I 70-73 glial cell derived neurotrophic factor Rattus norvegicus 208-212